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Abstract 
Calcineurin regulates APP metabolism: In vitro & In vivo studies 
Suruchi Utreja 
Aleister J. Saunders, Ph.D. 
Alzheimer’s disease (AD) is a complex neurodegenerative disease determined 
by the combination of environmental and genetic factors. AD is pathologically 
characterized by the accumulation of amyloid-β peptide (Aβ) and intraneuronal 
neurofibrillary tangles. Production of the Aβ peptide by the regulated intra-
membrane proteolysis of the β-amyloid precursor protein (APP) by the α, β and γ 
secretase enzymes is the central biological pathway in AD. Cognitive decline 
observed in AD models is dependent on Aβ generation. Of particular interest to 
the work presented here is the observation that APP proteolysis and levels of Aβ 
can be regulated by phosphorylation and phosphorylation-dependent events.  
 Downstream effects mediated by soluble Aβ aggregates include 
hyperactivation of a calcium (Ca2+) and calmodulin (CaM)-dependent, serine-
threonine protein phosphatase calcineurin (CaN). In our study we investigate the 
role of CaN in AD, and specifically its ability to regulate APP metabolism. CaN 
acts as heterodimer of CaNA (catalytic subunit) and CaNB (regulatory subunit) 
and its phosphatase activity can be inhibited using pharmacological drug FK506.  
 Using genetic and pharmacological manipulation of CaN in SH-SY5Y cells 
and cortical neurons as in vitro models and γ-secretase reporter fly and 
transgenic fly expressing human APP and BACE as our in vivo AD model 
(Chakroborty et al), we demonstrate that CaN regulates the proteolytic 
processing of APP. We also observe a decrease in Aβ and AICD levels on 
	   xvii	  
inhibition of CaN phosphatase activity. Furthermore, CaN inhibition rescues the 
Aβ-dependent, AD-like behavioral and cognitive deficits observed in our 
transgenic fly AD model. Overall, our results demonstrate CaN inhibition may 
rescue cognitive and neurodegenerative effects of Aβ by regulating APP 
proteolytic processing. Our work also lays the ground for designing better and 
more specific drugs that inhibit CaN activity and can act as a potential AD 
therapeutic. 	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CHAPTER 1: INTRODUCTION 
 
 
BACKGROUND AND SIGNIFICANCE: 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder 
characterized by global cognitive decline involving memory, orientation, judgment, 
and reasoning (Tanzi and L. Bertram 2005). Difficulty remembering names and 
recent events is often an early clinical symptom; apathy and depression are also 
often early symptoms (www.alz.org). Later symptoms include impaired judgment, 
disorientation, confusion, behavior changes and difficulty speaking, swallowing 
and walking (www.alz.org). It has been suggested that the prevalence of the 
disease doubles with every decade after the age of 60 (Tanzi and L. Bertram 
2005). AD is currently the sixth leading cause of death in U.S. Currently an 
estimated 5.4 million Americans of all ages have Alzheimerʼs disease 
(http://www.cdc.gov/nchs/data/dvs/deaths). No treatment is available to slow or 
stop Alzheimer’s disease. The U.S. Food and Drug Administration has approved 
five drugs (Aricept, Razadyne, Cognex, Exelon & Namenda) that temporarily 
improve the symptoms. The effectiveness of these drugs varies across the 
population. None of the treatments available today alter the underlying course of 
this terminal disease (www.alz.org). National cost of caring for AD pateints is 
projected to increase from $200 billion in 2012 to $1.1 trillion in 2050 (in 2012 
dollars) (Hebert et al., 2013). Therefore it is important to understand the genetic 
and molecular mechanisms leading to the development of AD in order to not only 
get a better understanding of the disease but also to develop potential novel 
therapeutics. 
	   2	  
 
GENETICS OF ALZHIEMERS DIESEASE: 
Aging and genetics play a major role in AD. Two main forms of AD exist: Early 
Onset Alzheimer’s disease (EOAD) and Late Onset Alzheimer’s disease (LOAD). 
EOAD is a rare, autosomal dominant form of the disease that develops in 
individuals before the age of 60 and accounts for approximately (1-5)% of total 
AD cases. EOAD cases can be attributed to mutations in three different genes: 
Amyloid Precursor Protein (APP; chromosome 21), Presenilin1 (PS1; 
chromosome 14) and Presenilin2 (PS2; chromosome 1) (Mullan et al., 1992, 
Schellenberg et al., 1992, Levy-Lahad et al., 1995). All the mutations in these 
genes account for 5% of total AD cases and alter APP processing and levels of 
β−Amyloid. 
     LOAD is the predominant form of AD and is prevalent after the age of 65 
(Goldman et al., 2011). These late onset cases are non-familial and sporadic, 
involving genetic variants of high prevalence and low penetrance. These gene 
variants do not cause AD but instead increase the risk of developing AD. To date, 
the only confirmed LOAD risk factor is the ε4 allele of apolipoprotein E gene 
(ApoE) (Saunders et al., 1993). The ApoE gene has 3 alleles called ε2, ε3, and 
ε4. ApoE ε4 has been associated with a high risk for AD and accounts for up to 
50% of the LOAD cases. However, genes that account for the other 50% of the 
LOAD cases are unknown.   Recent large GWASs have identified nine additional 
genes/loci for LOAD, including CR1, BIN1, CLU (a.k.a. APOJ), PICALM, 
MS4A4/MS4A6E, CD2AP, CD33, EPHA1 and ABCA7. (Lambert et al., 2009, 
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Harold et al., 2009, Seshadri et al., 2010, Hollingworth et al., 2011, Naj et al., 
2011) Although up to 80% of the AD risk is attributable to genetic factors, all of 
the known LOAD genes account for about 50% of the total genetic variance. This 
indicates that additional risk genes for LOAD remain to be identified. 
     Genome-wide linkage analysis and linkage disequilibrium studies have 
provided information on the existence of multiple putative AD genes on several 
chromosomes, with chromosomes 12, 10, and 9 being the strongest (Saunders 
et al., 2003, Blacker et al., 2003, Bertram and R. E. Tanzi 2008). These putative 
AD genes are believed to be regulators of APP metabolism and can modulate 
production or degradation of Aβ, thereby affecting the molecular pathology of the 
disease. To accelerate the understanding of a complex disease like AD, it is 
essential to identify genes that modulate AD risk and determine their mode of 
action.  
 
AD PATHOLOGY: 
The characteristic patho-biological hallmarks of AD include the presence of 
neurofibrillary tangles, senile plaques, and massive loss of neurons, primarily in 
cerebral cortex and hippocampus in the brain (De Strooper and W. Annaert 
2000). The neurofibrillary tangles are bundles of abnormal fibers found in the 
perinuclear cytoplasm. These fibers consist of twisted filaments composed of the 
hyperphosphorylated form of microtubule-associated binding protein Tau 
(Grundke-Iqbal et al., 1986, Selkoe 2002, Selkoe 1991). Senile plaques are 
extracellular deposits composed mainly of 4-kD β-amyloid (Aβ) peptide (Selkoe 
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1991). The Aβ peptides are generated by proteolytic processing from a larger 
Amyloid precursor protein (APP). The amyloid cascade hypothesis, the leading 
hypothesis of AD, states that misregulation of APP metabolism leads to 
accumulation of Aβ42  which initiates the AD pathogenesis (Tanzi and L. Bertram 
2005). Accumulation and aggregation of Aβ42 would further lead to pathological 
changes, including formation of neurofibrillary tangles, synaptic loss, neuronal 
death and eventually dementia (Hardy and D. J. Selkoe 2002, Hardy and D. J. 
Selkoe 2002), but this hypothesis is controversial and would need further 
investigation. 
 
ALZHEIMER’S AMYLOID PRECURSOR PROTEIN: 
 Aβ is part of and is generated from the larger β-Amyloid precursor protein (APP), 
which is a type I integral membrane protein with a relatively large extracellular 
domain, a small intracellular domain and a single transmembrane domain 
(Annaert and B. De Strooper 2002). The APP gene is located on the long arm of 
chromosome 21. In mammals APP is a member of a larger gene family that 
includes APP-like proteins, APLP1 and APLP2 (De Strooper and W. Annaert 
2000). Homologs of APP are also found in non-mammals like C. elegans (Apl-1) 
(Daigle and C. Li 1993) and D. melanogaster (APPL) (Martin-Morris and K. White 
1990).  The APP gene contains 19 exons, of which exons 7, 8 and 15 are 
alternatively spliced to produce at least 8 different splice variants of APP mRNA, 
of which APP695, APP751 and APP770 are the most predominant isoforms. 
APP751 and APP770 have an additional 56 amino acid domain (KPI domain), 
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which is functionally and structurally related to the Kunitz-type serine protease 
inhibitors (Ponte et al., 1988). The APP protein is ubiquitously expressed in all 
cells, with the different splice variants displaying differential tissue expression 
patterns. Of particular importance here is that the APP695 isoform, which lacks 
the KPI domain, is predominantly expressed in neurons while the APP751 and 
APP770 are expressed in non-neuronal cells(Sisodia et al., 1993, Zheng and E. 
H. Koo 2006). All the three isoforms have the same Aβ domain, transmembrane 
and intracellular domain and are thus potentially amyloidogenic. 
     All the isoforms of APP undergo maturation by N- and O- glycosylation of their 
extracellular/lumenal domains during their secretory pathway transit from the 
endoplasmic reticulum to the plasma membrane. The N-glycosylation of APP 
occurs in the endoplasmic reticulum and the cis-Golgi, and this APP is referred to 
as immature APP, which does not undergo proteolysis by the various secretases 
(Tomita et al., 1998). The immature APP then undergoes O-glycosylation in the 
medial and trans-Golgi. Once APP is both N- and O-glycosylated it is then 
referred to as mature APP and is now able to undergo proteolytic processing by 
the various secretases. Only a fraction of the mature APP is present at the 
plasma membrane where it is processed at the cell surface by α-secretase. In 
non-neuronal cells, APP is internalized within minutes of its arrival to the cell 
surface and delivered to the endosomes. β-secretase/BACE-1 (β-site APP 
Cleaving Enzyme), which is localized in the late golgi and endosomes can cleave 
APP during its endocytosis from the cell surface, if the α−secretase cleavage has 
not occurred first. α- and β-secretase cleavage is followed by the γ-secretase 
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cleavage in the transmembrane domain of APP (Figure 1-1A) (Koo and S. L. 
Squazzo 1994, Ponte et al., 1988, Thinakaran and E. H. Koo 2008, Small and S. 
Gandy 2006). Thus generation of Aβ is closely related to APP trafficking in the 
cell, especially in neurons since high level of neuronal expression of BACE-1 
preferentially leads to APP being channeled through the amyloidogenic-
processing pathway (pathway leading to Aβ production by cleavage of APP by β 
& γ-secreatse enzymes) (Thinakaran and E. H. Koo 2008). (Muresan et al., 2009) 
showed that APP is transported in neurites as already cleaved polypeptide rather 
than full-length protein. This indicates that in neurons the proteolytic cleavage of 
APP occurs first and the cleaved fragments then segregate into different vesicles 
that reach different destinations. Cleavage of mature APP by either α- or β- 
secretases produces three different C-terminal fragments. C99 and C89 are 
products of β- secretase cleavage whereas C83 is a result of the α- secretase 
cleavage (Selkoe 1991). The C-terminal or intracellular domain of APP contains 
various phosphorylation sites and functional motifs which play an important role 
in regulating its metabolism, trafficking and function (Thinakaran and E. H. Koo 
2008). 
     A number of physiological roles have been suggested for APP but its actual 
functions remain unclear. Studies done on APP fragments that contain the KPI 
domain indicate that APP could inhibit some serine proteinases involved in the 
blood coagulation pathway therefore suggesting that APP might play a regulatory 
role in the pathway (Smith et al., 1990, Van Nostrand et al., 1990). APP is also 
suggested to play a role in various physiological processes like cell proliferation, 
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cell survival, neuroprotection, memory enhancement, neuronal excitement and 
regulation of synaptic plasticity (Thinakaran and E. H. Koo 2008). Consistent with 
the above-mentioned trophic functions of APP, studies have also shown that 
APP deficient mice have reduced synaptic markers correlating with learning 
deficits and decreased synaptic plasticity (Dawson et al., 1999). Studies have 
also shown APP to be involved in regulating presynaptic expression of choline 
transporter (Wang et al., 2007). Loss of APP has been shown to lead to aberrant 
localization of the choline transporter to neuromuscular junctions (Wang et al., 
2007). This function is shown to be evolutionary conserved, as loss of APLP in 
Drosophila larvae results in decreased synaptic boutons in neuromuscular 
junctions of Drosophila (Ashley et al., 2005). These findings therefore suggest 
that APP might play an important role in the development of the nervous system 
and maintaining synapse structure and function. 
 
REGULATED INTRA MEMBRANE PROTEOLYSIS OF APP: 
APP is subject to proteolytic processing by different sets of enzymes and is 
thought to undergo proteolytic processing either in the secretory pathway after 
undergoing maturation, on the plasma membrane or in the endocytotic cycle. 
Three different secretase enzymes namely: α-, β- and γ-secretase are known to 
cleave APP (Suzuki and T. Nakaya 2008). ADAM family (A Disintegrin and 
Metalloprotease) namely, Tumour necrosis factor-α Converting Enzyme (TACE 
or ADAM17), (a disintegrin and metalloprotease) ADAM9, and ADAM10 and 
BACE2 are candidate α-secretases. The enzyme capable of performing β-
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secretase cleavage is known as BACE1. γ-secretase is a high molecular weight 
multimeric complex composed of the 4 proteins PS1, Pen2, Aph-1 and Nct 
(Edbauer et al., 2003, Chen et al., 2002). APP undergoes proteolytic processing 
by two different pathways: Amyloidogenic pathway or the non-amyloidogenic 
pathway respectively (Figure 1-1A). In the non-amyloidogenic, the α-secretase 
cleaves APP between the Lys16 and Leu 17 within the Aβ domain. This cleavage 
releases a large soluble ectodomain fragment called s-APPα into the 
extracellular space and results in the retention of a membrane bound COOH-
terminal fragment called C83 (Esch et al., 1990). Since α-secretase cleaves 
within the Aβ of APP, cleavage by α-secretase is said to preclude the formation 
of Aβ. The membrane bound C-83 domain of APP is subsequently cleaved by 
another secretase called the γ-secretase to generate a 22-24 amino acid (~3kD) 
residue called the p3 which is non-amyloidogenic and is released in the 
extracellular space and a 57-58 C-terminal residue APP intracellular domain 
(AICD) (Sisodia et al., 1990, Passer et al., 2000) (Figure 1-1B). Alternatively 
during amyloidogenic APP processing, the initial cleavage of APP can be carried 
out by β-secretase which cleaves at N-terminus of, the Aβ domain at amino acid 
16 of APP releasing a soluble fragment s-APPβ, into the extracellular space and 
retaining a membrane bound COOH-terminal 99 amino acid fragment C99 that 
begins at residue 1 of the Aβ region (Seubert et al., 1993). Subsequent cleavage 
of the membrane bound C99 by γ-secretase results in the generation of multiple 
peptides, the most common being Aβ40 and Aβ42, and also results in a C-
terminal AICD fragment (Figure 1-1B). Aβ40 comprises of approximately ~90% 
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of the secreted Aβ in contrast to Aβ42 which is only 10% of the total secreted Aβ 
(Seubert et al., 1993). In spite of this difference, Aβ42 is still the most 
predominant species found in plaques in AD patients. This could be because 
Aβ42, once generated, can form insoluble amyloid aggregates more rapidly than 
Aβ40. Studies have shown that most of the s-APPα is by α-secretase occurring 
on the APP at the plasma membrane (Sisodia et al., 1990). It has also been 
shown that s-APPα can also be produced during the secretory intracellular 
trafficking of APP (De Strooper et al., 1993). 
     AICD has the ability to transactivate gene expression. It associates with an 
adaptor protein, Fe65, and translocates into the nucleus where it binds with a 
histone acetyl transferase (HAT) Tip60 forming a trimeric complex that can 
regulate gene transcription (De Strooper and W. Annaert 2000). (Cupers et al., 
2001) The γ-secretase complex therefore not only plays an important role in Aβ 
production but also controls AICD mediated intracellular signaling which in turn 
might be responsible in regulating expression of genes involved in the disease. 
     AICD contains the 682YENPTY687 motif that is required for its interaction with 
several cytoplasmic proteins termed APP adaptor proteins (Ando et al., 2001). In 
previous studies it was shown that the 682YENPTY687 motif of AICD is required for 
the interaction with Fe65 (Borg et al., 1996). Phosphotyrosine interaction 
domains (PI domains) of Fe65, Fe65-like Fe65L1, Fe65L2, X11, X11-like X11L, 
X11L2 and mammalian disabled-1 (mDAB1) interact with this motif (Borg et al., 
1996, Ando et al., 2001). The AICD sequence also contains eight potential 
phosphorylation sites of which seven sites Tyr653, Ser655, Thr668, Ser675, 
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Tyr682, Thr686 and Tyr687 were reported to be phosphorylated in the brains of 
AD patients (Shibasaki et al., 2002, Lee et al., 2003). It has been shown that 
phosphorylation of AICD at specific sites affects its interaction with the 
cytoplasmic adaptor proteins, in particular Fe65. Phosphorylation of AICD at 
Y682 residue was shown to decrease binding of Fe65 and X11 (Zambrano, Bruni 
et al. 2001) while phosphorylation at Thr668 is necessary for Fe65 binding to 
AICD and is required for AICD mediated transcriptional activation of various 
genes (Chang, Kim et al. 2006). Studies have shown that inhibition of Thr668 
phosphorylation of AICD reduces its nuclear translocation and thereby it’s 
transcriptional activity (Kinoshita, Whelan et al. 2002; Chang, Kim et al. 2006). 
On the contrary there have been reports suggesting that phosphorylation of APP 
at Thr668 diminishes its interaction with Fe65 (Suzuki et al 2001). Fe65 also has 
the ability to interact with several other proteins, one of them being TIP60 (TAT-
interacting protein) resulting in the formation of the AICD-Fe65-TIP60 complex 
that then translocates to the nucleus stimulation transcription of specific genes 
(Cao and T. C. Sudhof 2001). This property of AICD has been used to monitor 
APP proteolysis and for identification of putative regulators of APP metabolism 
by monitoring AICD production in cell culture (Zhang, Khandelwal et al. 2007). 
     Studies have implicated AICD to be involved in regulating transcription of 
various genes, one of them being GSK-3β encoding the enzyme glycogen 
synthetase kinase - 3β(Kim, Kim et al. 2003) which plays a key role in the 
pathogenesis of Alzheimer’s disease, Huntington’s disease, and bipolar disorder 
(Jope and Johnson 2004). AICD was also shown to induce expression of other 
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genes including KAI1, the metastasis suppressor gene (Baek, Ohgi et al. 2002); 
BACE and Neprilysin involved in Aβ homeostatsis (Kim, Kim et al. 2003); HES1 
involved in differentiation and EGFR, ACE1, ACE2 and LFP1 involved in 
thymidylate synthetase (Muller, Meyer et al. 2008). Therefore since AICD also 
regulates genes involved in AD pathogenesis it can be hypothesized that AICD 
may be an important contributing factor to the AD phenotype. 
 
PHOSPHORYLATION DEPENDENT REGUATION OF APP METABOLISM: 
It is now been widely accepted that abnormal processing of APP can contribute 
significantly to AD. Data from several groups have revealed that APP processing 
can be regulated by phosphorylation and phosphorylation-dependent events 
(Suzuki and T. Nakaya 2008). Interestingly, in addition to hyperphsophorylated 
Tau, hyperphosphorylated APP has been observed in brains of AD patients 
(Muresan et al., 2009). APP is known to be phosphorylated, both in its 
extracellular and intracellular domains. APP ectodomain, is phosphorylated at 
Ser198 and Ser206 by ecto-casein kinases 1(CK1) and 2(CK2) (Walter et al., 
1997). It has been suggested that phosphorylation of these amino acids occurs  
in post-golgi secretory compartment and at the cell surface. The cytoplasmic 
domain of APP is comprised of seven potential phosphorylation sites. Seven of 
these phosphorylation sites were recently shown to be phosphorylated in AD 
brains, i.e.Tyr653, Ser655, Thr668, Ser675, Tyr682, Thr686 and Tyr687 
(APP695 isoform numbering) (Takahashi et al., 2008). Thr668 residue on APP is 
known to be phosphorylated in AD brains and is considered as one of the major 
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sites which plays a role in regulation of APP proteolysis. Thr668 phosphorylation 
of APP is mediated by neuronal cyclin-dependent protein kinase 5 (cdk5), cdc2 
protein kinase (cdc2), glycogen synthase kinase 3β (GSK-3β), or c-jun N-terminal 
kinases (Suzuki and T. Nakaya 2008, Muresan and V. Muresan 2005). Thr668 
phosphorylation of APP has been shown to facilitate its cleavage by β-secretase 
leading to increased levels of Aβ (Sodhi et al., 2008). However, a recent study 
reported that phosphorylation of APP at Thr668 inhibits its cleavage by γ-
secretase, thereby decreasing the Aβ generation (Feyt et al., 2007). Also, Thr668 
phosphorylation of APP affects interaction of AICD with its binding proteins such 
as adaptor protein Fe65 and eventually AICD mediated gene transactivation 
(Sodhi et al., 2008, Tamayev et al., 2009, Vieira et al., 2009). Thus the precise 
function of APP phosphorylation at Thr668 is controversial and remains unclear. 
     Ser655 phosphorylation of APP-CTF’s has been detected in AD brains. PKC 
and CAMKIIA are the kinases involved in the phosphorylation of Ser655. 
Phosphorylation of Ser655 enhances its secretory trafficking via post trans-golgi 
network vesicles and leads to increased production of cytoprotective s-APPα 
(Vieira et al., 2009). In addition to serine/threonine phosphorylation of APP, 
tyrosine phosphorylation of APP is also related to AD. There has been evidence 
suggesting that non-phosphorylated state of APP at Tyr687 decreases APP 
processing by α- and γ-secretase, resulting in decreased levels of AICD 
(Takahashi et al., 2008). Phosphorylation of Tyr687 is also responsible for its 
targeting and processing via different pathways such as endocytosis (Rebelo et 
al., 2007). Overall, tyrosine phosphorylation of APP is related to cell signaling by 
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determining the expression of AICD, which in turn regulates gene transcription. 
Of particular interest is the observation that metabolism of APP via different 
proteolytic processing pathways is phosphorylation dependent and has been 
affects levels of Aβ. The key players in controlling phosphorylation dependent 
APP metabolism changes are the protein kinases and the phosphatases, as well 
as their corresponding regulatory proteins (da Cruz e Silva et al., 2004). While 
the role of the protein kinases in APP metabolism has been relatively well studied, 
considerably less effort has been dedicated to elucidate the role played by 
protein phosphatases. Abnormal phosphorylation of APP can result from 
physiological imbalance between the relevant kinase and phosphatase activities 
acting on it, so it is equally important to evaluate the role played by the protein 
phosphatase in APP metabolism. 
 
GENETIC STUDIES IMPLICATE OF ABNORMAL APP PROCESSING: 
To date there are four genes that have been implicated in EOAD. Genome-wide 
linkage analysis and linkage disequilibrium studies, reported the presence of 
candidate genes on Chromosomes 9, and 10 that can account for the remaining 
risk of LOAD (Li et al., 2002, Zuchner et al., 2008). These genes are believed to 
be regulators of APP metabolism and can modulate production/degradation of Aβ, 
thereby affecting the molecular pathology of the disease. Hence using an AICD 
based functional screen, ~700 genes in these chromosomal regions were tested 
for their ability to regulate APP metabolism (Zhang and Khandelwal et al, 
unpublished data). The screen made use of the gene transactivation properties 
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AICD-Fe65-Tip60 trimeric complex. APP695 was engineered with a Gal4 (yeast 
transcription factor) DNA binding domain to form APP-Gal4 fusion protein. This 
APP- GAL4 fusion protein along with a GAL4- UAS reporter construct bearing the 
luciferase gene were stably overexpressed in SHSY5Y-APPGAL4 cells. In the 
cells APP-Gal4 undergoes proteolysis to produce AICD-Gal4 instead of just 
AICD. AICD-Gal4 after forming a trimeric complex with endogenous Fe65 and 
Tip60 activates transcription of a firefly luciferase gene under the control of Gal4-
UAS (GAL4-UAS-LUC) (Zhang et al., 2007). Further RNAi knockdown of all the 
candidate genes were done in SHSY5Y-APP-Gal4 cells. The principle underlying 
it was that if any of these genes is involved regulation of APP metabolism, 
knockdown of that particular gene will alter APP proteolysis which will lead to a 
change in amount of AICD being produced and hence AICD-mediated 
transcription of luciferase gene activity (Figure 1-1C) (Khandelwal & Zhang et al). 
     We identified more than thirty genes whose knockdown lead to significant 
changes in luciferase activity. Two of these genes stood out, because they 
encode for the catalytic and the regulatory subunit of the serine/threonine protein 
phosphatase Calcineurin (CaN) (unpublished data). PPP3CB or CaNAβ (catalytic 
subunit of Calcineurin) is located on chromosome 10 and PPP3R2 or CaNB2 
(regulatory subunit of Calcineurin) is located on chromosome 9 (Figure 1-1D). 
The mechanism by which CaN regulates APP metabolism still needs to be 
identified. In our study we investigate if CaN regulates APP proteolytic 
processing and discuss the potential mechanisms of action. 
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CALCINEURIN 
STRUCTURE:  
Calcineurin (CaN) is a member of the serine/threonine protein phosphatase 
family and the only known phosphatase activated by Ca2+ and Calmodulin (CaM) 
(Shibasaki et al., 2002, Rusnak and P. Mertz 2000). CaN is a heterodimer 
consisting of a 58-64 kDa catalytic subunit (CaNA) tightly bound to a 19 kDa 
regulatory subunit (CaN B) (Rusnak and P. Mertz 2000). CaNA is composed of a 
catalytic domain and a regulatory domain that contains a CaNB binding 
sequence, a CaM binding domain and an autoinhibitory domain (Klee et al., 
1979) (1-1E). The phosphatase becomes activated when Ca2+/CaM binds to it, 
which triggers the release of the autoinhibitory domain from catalytic active site 
(Klee et al., 1979, Rusnak and P. Mertz 2000) (Figure 1-1F). CaNA can also be 
activated by proteolytic cleavage of the autoinhibitory domain, resulting in a 
Ca2+/CaM- independent active phosphatase (Klee et al., 1998, Perrino et al., 
1995, Wu et al., 2004, Rusnak and P. Mertz 2000). Three mammalian isoforms 
of CaN A (α, β, γ) have been identified, and their amino acid sequences have 
been highly conserved from yeast to mammals (Shibasaki et al., 2002, Rusnak 
and P. Mertz 2000). CaNAα and CaNAβ are ubiquitously distributed, while 
CaNAγ is specifically expressed in the testis.  
     CaNB has two mammalian isoforms CaNB1 and CaNB2, which are also 
highly conserved and have four Ca2+ binding “EF-hand” motifs each. CaNB1 is 
ubiquitously expressed as a heterodimer with CaNAα or β, while CaNB2 binds to 
CaNAγ and is expressed only in testis (Rusnak and P. Mertz 2000). The CaNB 
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subunit is myristolated at the N-terminus, which has been suggested to assist the 
interaction of CaN with lipid membranes and its localization at the plasma 
membrane (Shibasaki et al., 2002). Conversely, there have been reports 
suggesting that this interaction of CaNB with lipid membranes is dependent on 
phospholipid-binding site located on the CaNB rather than the myroistylation, 
which helps in its association with cytoskeleton (Rusnak and P. Mertz 2000, 
Perrino and B. A. Martin 2001). 
 
TISSUE SPECIFIC DISTRIBUTION AND LOCALIZATION: 
 CaN is known to have a ubiquitous distribution and is present in a variety of 
mammalian tissues with 10-20 times higher concentration in the brain tissue 
(Rusnak and P. Mertz 2000, Shibasaki et al., 2002). It compromises 1% of the 
total protein content of the brain (Klee et al., 1988, Yakel 1997, Rusnak and P. 
Mertz 2000). More than 50% of CaN is found to be membrane bound or bound to 
the cytoskeleton elements (Yakel 1997). CaN has been detected in the nucleus 
as well where it has been found to co-localize with NFAT (Nuclear Factor of 
Activated T cell) in T-lymphocytes (Shibasaki et al., 1996, Rusnak and P. Mertz 
2000). CaN is found in the hippocampus and the striatum in its highest 
concentrations (Polli et al., 1991, Rusnak and P. Mertz 2000, Shibasaki et al., 
2002). In rat brain, CaNA α and CaNAβ isoforms are found to be differentially 
expresssed. CaNAα presence is more abundant than CaNAβ  isoform (Kuno et 
al., 1992, Rusnak and P. Mertz 2000). However, it has been suggested that in 
the brain the two CaNA isoforms have different distribution within the cell 
	   17	  
(Shibasaki et al., 2002), with CaNAα form being present in the nucleus and the 
CaNAβ isoform in the cytoplasm (Usuda et al., 1996, Rusnak and P. Mertz 2000, 
Shibasaki et al., 2002). In neurons, CaN is present in both soma and the 
dendrites, in close proximity with post-synaptic densities (PSD), plasma 
membrane, microtubules present in dendrites and somal organelles (Klee et al., 
1988, Rusnak and P. Mertz 2000). CaN expression levels are reported to be 
undetectable in the very young rat brain during its developmental stage. Within a 
month after development, CaN levels increase and remain at a high level 
throughout adulthood (Takahashi et al., 2000, Rusnak and P. Mertz 2000, 
Shibasaki et al., 2002). 
 
CALCINEURIN PHOSPHTASE ACTIVITY AND ITS REGULATION: 
CaN phosphatase activity is dependent on its binding to Ca2+ binding proteins, 
Calmodulin (CaM) & the regulatory subunit CaNB (Shibasaki et al., 2002, Rusnak 
and P. Mertz 2000). Ca2+ levels in the cell increase leading to the binding of Ca2+ 
to the 4-EF hand motifs present in CaM and CaNB. This binding of Ca2+ to CaM 
and CaNB is followed by their activation. Once activated CaM and CaNB bind to 
CaNA, leading to the removal of the autoinhibitory domain from the catalytic site 
of CaNA. Removal of the autoinhibitory domain causes a structural change in 
CaNA and its complete activation (Figure 1-1F). This dependence of CaM based 
stimulation of CaN, on Ca2+ levels, makes this phosphatase respond to even very 
narrow Ca2+ thresholds following cell stimulation.  Apart from CaM and CaNB 
dependence, deletion of the CaNA autoinhibitory domain can also lead to its 
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constitutive activation without being dependent on Ca2+ levels. It has been 
reported that a single amino acid mutation in CaNA, making it a dominant 
negative mutant, has been found to suppress endogenous CaN (Rusnak and P. 
Mertz 2000, Shibasaki et al., 2002). NFAT translocation dependent on 
dephosphorylation of NFAT by an active CaN, has been shown to be effectively 
suppressed by substituting the histidine residues of CaNA to glutamate (H101Q, 
H160Q and H290Q) (Rusnak and P. Mertz 2000). 
     The role of CaNB in CaN activation and its specific function is not clear. There 
has been evidence showing that binding to CaNB & CaM activates CaNA. 
Conversely, removal of the autoinhibitory domain from CaNA leads to its 
independent activation. Therefore, it has been suggested that Ca2+ binding to 
CaNB plays a structural rather than a regulatory role for CaNA activation 
(Shibasaki et al., 2002, Rusnak and P. Mertz 2000). Mutants of the latch domain 
(binding site for drug immunophilin complex) of CaNB, suppressed CaN activity, 
supporting the above hypothesis (Shibasaki et al., 2002). Hence, conformational 
folding of CaNA by CaNB is suggested to be important for allosterically activating 
CaNA (Rusnak and P. Mertz 2000, Shibasaki et al., 2002). 
 
CALCNEURIN SUBSTRATES: 
CaN has a wide substrate specificity. Substrates of CaN have been shown to be 
involved in various signal transduction pathways and diseases (Klee et al., 1988, 
Pallen and J. H. Wang 1985, Morioka et al., 1999, Rusnak and P. Mertz 2000). 
These substrates include NO synthase, dynamin (a GTPase involved in 
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endocytosis), the transcription factor Elk-1, the heat shock protein hsp25, tau, the 
NMDA receptor (Dawson et al., 1993, Herskovits et al., 1993, Sugimoto et al., 
1997, Gaestel et al., 1992, Goto et al., 1985, Rusnak and P. Mertz 2000, 
Shibasaki et al., 2002). CaN is also known to dephosphorylate nuclear factor of 
activated T- cells (NFAT) (Abdul et al., 2009, Rusnak and P. Mertz 2000), cAMP 
response element binding (CREB) (Bito et al., 1996), PP1 (Foster et al., 2001, 
Mulkey et al., 1994), microtubule-associated protein tau (Brion et al., 1995, Liu et 
al., 1991), glycogen synthase kinase-3 beta (GSK- 3) (Kim et al., 2009); and Bcl-
2 associated death protein (BAD) (Wang et al., 1999).  
     CaN dephosphorylates phosphoserine and phosphothreonine residues 
preferentially but can also dephosphorylates phosphotyrosine with a lower order 
of magnitude (Rusnak and P. Mertz 2000). The RII subunit of cyclic AMP-
dependent protein kinase is a very well known substrate of CaN. In order to 
measure the CaN phosphatase activity in cells or tissue extracts, the 81-99 
residue peptide for the RII subunit is used (Shibasaki et al., 2002). This peptide is 
specific to CaN phosphatase activity and does not get dephosphorylated by other 
phosphatases like PP1, PP2A, and PP2C.  
 
ACTIVATORS AND INHIBITORS OF CALCINEURIN: 
CaN is shown to be activated by increase in levels of calcium intracellularly or 
from the extracellular stores. This leads to CaM mediated activation of CaN (Klee 
et al., 1979). CaN can also be activated by pharmacological drugs such as 
Ionomycin and PMA (Phorbol 12-myristate 13-acetate). These drugs work by 
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increasing the intracellular levels of Ca2+. CaN phosphatase actitivty can be 
inhibited by two well-known inhibitors named FK506 and CsA (Figure 1-1G) (Liu 
et al., 1991). FK506 (tacrolimus) forms a complex with FK506-binding protein 
(FKBP12) and together they bind to CaN and inhibit CaN mediated 
dephosphorylation of its substrates (Schreiber and Crabtree, 1992). FK506 is an 
FDA approved drug used for organ transplantation but serious side effects such 
as neurotoxicity and nephrotoxicity have been observed in the patients. FK506 
treated patients have been detected with tremors, aphasia, cortical blindness, 
hallucinations, and memory impairment (Lee et al., 2008; Wijdicks et al., 1994). 
Cyclosporin A (CsA) also acts by forming a complex with Cyclophilin A and inhibit 
CaN phosphatase activity (Liu et al., 1991). In contrast to the calcineurin 
inhibitors discussed above, which inhibit CaN phosphatase activity, a short 
peptide, VIVIT, specifically inhibits CaN mediated NFAT activation (Hudry 
et al., 2012). It interacts with the calcineurin-binding site for NFAT on CaN 
and thus prevents nuclear translocation without affecting CaN 
phosphatase activity. 
     AKAP-79 (A-kinase anchoring protein) is also an important endogenous 
inhibitor of CaN (Kashishian et al., 1998). AKAP-79 has been shown to bind to 
both PKA (protein kinase A) and CaN in post-synaptic densities (Coghlan et al., 
1995). Apart from AKAP-79, CHP (Calcineurin Homologous protein), Cabin1/cain 
and CBP1/calcipressin are also known to inhibit CaN activity (Sun et al., 1998, 
Gorlach et al., 2000, Lin et al., 1999). CHP is homologous to CaNB and directly 
binds to CaN and inhibits its phosphatase activity (Lin et al., 1999). Cabin1/cain 
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also binds to CaN and inhibits CaN in a phosphorylation dependent manner(Sun 
et al., 1998). On the other hand CBP1/calcipressin acts as a feedback inhibitor of 
CaN signaling(Gorlach et al., 2000).  
 
CALCINEURIN AND ALZHEIMER’S DIESEASE: 
 
CaN plays a very important role in AD.  CaN, being a serine/threonine specific 
phosphatase, has been associated with dephosphorylation of many genes that 
are an important part of the signaling pathways contributing to AD. Specifically, 
CaN has been shown to mediate the neurodegenerative effects of Aβ (Reese et 
al., 2008, Wu et al., 2010, Agostinho et al., 2008, Abdul et al., 2009, Loo et al., 
1993). Aβ produced by the amyloidogenic processing of APP is responsible for 
perturbing the intracellular levels of Ca2+ (Reese et al., 2008). Specific species of 
Aβ can aggregate to form Ca2+ channels in synthetic bilayer membranes (Arispe 
et al., 1993). Oligomeric species of Aβ alter the cytosolic Ca2+ levels by cellular 
membrane disruption (Reese et al., 2008). Ca2+ dyshomeostasis leads to 
activiation of various kinases and phosphatases including the serine/threonine 
phosphatase CaN. CaN hyperactivation results in dephosphorylation of 
numerous genes thought to play a role in AD pathogenesis, including phospho-
CREB (Bito et al., 1996), phospho-NFAT (Abdul et al., 2009), phospho-Tau (Liu 
et al., 2005), phospho-BAD (Wang et al., 1999, Asai et al., 1999, Dineley et al., 
2007) and phospho-Gsk3β  (Kim et al., 2009). Discussed below are the details of 
how CaN dephosphorylates these individual genes and contributes to AD 
pathogenesis by instigating loss of synaptic plasticity, dendritic spine loss, 
microtubule dysfunction, apoptosis, and excitotic cell death. 
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     However, the role of CaN in the brain may be very complicated. CaN isolated 
from the human brain dephosphorylates, Tau at Ser-262 and Ser-396 indicating 
its role in neurofibrillary tangles associated degeneration in AD (Rahman et al., 
2006). In mice, overexpression of CaN leads to altered synaptic function along 
with deficits in memory retention (Kayyali et al., 1997, Malleret et al., 2001). On 
the other hand, knockdown of CaN activity facilitates long-term potentiation (LTP) 
with improvement in learning and memory (Malleret et al., 2001). Also in Purkinje 
cells, complete knockdown of CaN in the anterior cortex impairs cognition by 
affecting post synaptic LTP (Zeng et al., 2001). In addition, upregulation of CaN 
activity in aged rats negatively correlates with the cognitive performance (Foster 
et al., 2001). Contrariwise, use of autoinhibitory peptide to downregulate CaN 
activity has shown to improve memory in rodents (Malleret et al., 2001). 
Transgenic Tg2576 mice (AD mouse model), which accumulate Aβ and develop 
cognitive impairments prior to plaque deposition, have high CaN activity in 
central nervous system (CNS). FK506 mediated inhibition of CaN in these mice 
leads to improved memory function, indicating that CaN is part of the Aβ 
mediated memory loss pathway (Dineley et al., 2007). It has been shown that 
exogenous application of synthetic amyloid-β or oligomeric aggregates to 
cultured cells leads to an increase in Ca2+ levels along with increased CaN 
activity (Reese et al., 2008). Furthermore, Aβ induces neuronal apoptosis 
through a CaN-dependent mechanism (Agostinho and C. R. Oliveira 2003). 
Taken together, these studies suggest that CaN is the major phosphatase 
involved in cognitive and neurodegenerative effects of Aβ. However, the 
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relationship between Aβ and CaN is yet to be established. Overall, CaN has 
been linked to AD through multiple signaling cascades discussed above but we 
are interested in investigating and defining the relation between CaN and 
Amyloidβ precursor protein. 
 
CALCINEURIN AND APP METABOLISM: 
Previously, one cDNA microarray analysis has shown that CaNAβ is the most up-
regulated gene in brain lesions of the early stage of AD (Hata et al., 2001).  RT-
PCR analysis from the same study also confirmed that CaNAβ was generally 
upregulated in the hippocampus of the early stage of AD (Hata et al., 2001). The 
exact mechanism for upregulation of CaNAβ in the AD brain remains unknown. 
In our lab we also identified CaNAβ as a putative gene that could regulate APP 
metabolism using an AICD based functional screen to identify APP metabolism 
regulators (Zhang and Khandelwal et al unpublished data). CaNAβ knockdown in 
SH-SY5Y APP-Gal4 cells lead to a decrease in AICD-mediated gene 
transcription. On the other hand, CaNAβ overexpression lead to significant 
increase in AICD-mediated gene transcription. This data suggested that CaN 
plays a reproducible role in APP metabolism. Next, we used FK506 a 
pharmacological inhibitor of CaN in SH-SY5Y APP-Gal4 cells and observed a 
decrease in AICD-gene transcription similar to knockdown of CaNAβ. As 
discussed in the sections above, Aβ is very well studied for its ability to alter CaN 
activity. Also pharmacological inhibition of CaN has been shown to decrease Aβ 
levels in various AD models. What has not been well studied is how does CaN 
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alter levels of Aβ. Therefore, our study focuses on determining if CaN alters APP 
proteolysis and hence affects the levels of Aβ, potentially forming a feed-back 
loop (Figure 1-1H). 
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SUMMARY OF THE DESSERTATION RESEARCH: 
 A disturbance of Ca2+ homeostasis is believed to play an important role in the 
neurodegeneration of the brains of Alzheimer’s disease (AD) patients (LaFerla 
2002). CaN is a Ca2+ dependent phosphatase whose levels and activity are 
altered in brains of AD models (Dineley et al., 2007). CaN, being serine/threonine 
specific phosphatase, has been shown to dephosphorylate Tau, the main 
component of neurofibrillary tangles (Rahman et al., 2006). CaN has been shown 
to be activated by Aβ and is involved in its downstream signaling pathways 
(Reese et al., 2008, Wu et al., 2010, Agostinho et al., 2008, Abdul et al., 2009, 
Loo et al., 1993, Dineley et al., 2007). FK506 mediated inhibition of CaN activity 
also decreases levels of Aβ (Dineley et al., 2007, Hong et al., 2010, Spires-Jones 
et al., 2011, Taglialatela et al., 2009). Together all these studies reinforce the role 
of CaN in AD.  
     In our study, we specifically wanted to determine, how CaN alters levels of Aβ 
and we looked at APP metabolism changes in presence/absence of CaN. Our 
study demonstrates that inhibition of CaN regulates APP processing in vitro and 
in vivo. We observed that CaNAβ knockdown and FK506 treatment decreased 
AICD mediated reporter gene expression in human SH-SY5Y cells and in γ-
secretase reporter flies, while CaNAβ over-expression increased reporter 
expression in human SH-SY5Y cells. In rat primary cortical neurons, FK506 
treatment increased levels of total and phospho-Thr668 APP-CTFs and reduced 
Aβ and AICD levels without altering FL-APP, sAPP total, sAPPβ and phospho-
Thr668 FL-APP levels. These results suggest that inhibition of CaN phosphatase 
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activity decreases the amount of APP-CTF’s undergoing cleavage by γ-secretase. 
This decrease in γ-secretase cleavage seems to be APP specific since no 
changes in another γ-secretase substrate, NotchΔE, were observed. Given these 
anti-amyloidogenic effects induced by FK506 in neurons, we tested whether 
FK506 altered in vivo APP processing in a similar fashion. Using a Drosophila 
AD model, we inhibited CaN using FK506 and observed increased APP-CTFs 
and decreased Aβ levels. Additionally, the Aβ induced neuroanatomical and 
memory deficits previously observed in this AD model were rescued upon 
administration of FK506. Results from our study suggest CaN regulates APP 
cleavage by modulating the proportion of APP-CTFs undergoing γ-secretase 
cleavage. 
     While we observe similar decreases in Aβ levels and improved cognitive 
function in AD models treated with FK506, our study differs from these other 
studies because it demonstrates that CaN modulates APP processing. 
Greengard and colleagues demonstrated that CaN regulates Aβ formation 
(Desdouits et al., 1996) in cell-free membrane extracts, however there has been 
no demonstration, to our knowledge, that CaN regulates APP processing in 
neurons or in living organisms. In addition to decreased Aβ levels, we observe 
decreased AICD levels and increased APP-CTF levels. Similar changes are 
observed when these in vivo AD models are treated with L-685, 458, an inhibitor 
of γ-secretase activity (Chakraborty et al., 2011). These results imply that FK506 
mediated inhibition of CaN is regulating γ-secretase mediated cleavage of APP-
CTFs. To explore this possibility, we investigated the effect of CaN inhibition on 
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Notch cleavage, another substrate of γ-secretase.  Unlike L-685, 458 treatment, 
FK506 treatment did not alter NICD levels, suggesting that the mechanism by 
which FK506 is regulating APP proteolysis does not involve a general inhibition 
of γ-secretase activity.   
     Given that CaN is a serine/threonine phosphatase; we set out to determine 
the role of APP phosphorylation in the FK506-induced changes we observe. The 
role of Thr668 phosphorylation on APP processing is controversial, with reports 
concluding that Thr668 phosphorylation has increased, decreased, or has no 
effect on Aβ levels (Sano et al., 2006, Lee et al., 2003, Vingtdeux et al., 2005, 
Feyt et al., 2007). We observed that FK506 treatment of neurons resulted in 
increased phospho-Thr668 APP-CTFs levels. This increase could drive APP 
processing changes or could be a consequence of APP processing changes. To 
further explore these possibilities, we treated HEK-293 cells transfected with wild 
type or Thr668Ala APP with FK506. This treatment resulted in a modest increase 
in APP-Thr668Ala-CTFs levels and a more robust increase in APP-CTF levels. 
Unlike FK506 treatment of neurons, however, treatment of these transfected 
HEK293 cells resulted in an increase in FL-APP. Therefore when quantifying the 
effect of FK506 on these cells we do not observe a significant increase in the 
ratio of APP-CTF to FL-APP for the wild-type or mutant APP constructs. These 
results differ from the changes we observed on endogenous APP-CTFs in 
neurons and are most easily explained by the inherent differences between APP 
exogenously expressed in HEK293 cells and endogenous expression of APP in 
primary neurons. This may be particularly true for CaN mediated phenomena, 
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since CaN is a calcium regulated phosphatase and neurons tightly regulate Ca2+ 
signaling given the large number of Ca2+ dependent events that occur within 
neurons (Wu et al., 2010). Given these observations, we cannot conclusively 
determine the role of Thr668 in FK506 induced changes in APP processing. 
     The effects we observe in neurons are generally recapitulated in FK506 
treated AD flies. We observe increased levels of APP-CTFs along with 
decreased Aβ levels, decreased AICD-mediated reporter gene expression, and 
no significant changes in FL-APP. Unlike neurons, however, the increase 
observed in AD fly phospho-Thr668 APP-CTFs did not reach statistical 
significance. One reason for this discrepancy may be the cell type heterogeneity 
of whole Drosophila brain compared to a relatively homogeneous culture of 
cortical neurons. It is also is possible that different cell types within fly brain have 
different responses to FK506 leading to differences in APP phosphorylation 
between cell types. The altered APP processing and phosphorylation observed in 
HEK293 cells in response to FK506, compared to neurons, could be evidence of 
such cell type specificity. Alternatively, Thr668 phosphorylation may not be 
involved in mediating the FK506 induced changes in AD fly brains. Finally, we 
observe robust improvement in the Aβ induced deficits in mushroom body 
neuroanatomy and memory upon FK506 treatment. The changes we observe in 
APP-CTFs and Aβ levels lead us to suggest that changes in APP processing are 
responsible for the improvements seen in the AD flies. It is possible that Aβ 
degradation could be increased by FK506 treatment. In fact, Hong et al observed 
that the FK506 induced improvements in APP/PS1 AD mouse model 
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corresponded to increased levels of the Aβ degrading protease, MMP9, in 
astrocytes (Hong et al., 2010).  
     Taken together, our findings demonstrate that pharmacological inhibition of 
CaN using FK506 leads to altered APP proteolysis resulting in decreased levels 
of Aβ and AICD. These changes coincide with a rescue of Aβ-dependent  
cognitive and neuroanatomical deficits. Decreased Aβ levels seem to be due to 
decreased APP-CTF cleavage by γ−secretase. This decrease in γ−secretase 
cleavage seems to be specific to APP since Notch cleavage wasn’t affected. 
APP cleavage by γ−secretase could be specifically modulated by de-
phosphorylation of APP at Thr 668 or other Ser/Thr residues. In addition, FK506 
may alter phosphorylation of one or more of the γ−secretase components leading 
to changes in substrate specificity or activity. FK506 treatment could also alter 
APP subcellular localization / trafficking, which is an important determinant of 
APP proteolysis. Such changes could regulate the availability of APP-CTFs to 
γ−secretase, or vice versa. The exact mechanism involved is under investigation. 
     To our knowledge our study is the first to directly demonstrate the ability of 
CaN to regulate neuronal APP processing (Figure 1-1H). Overall our results 
support previous work demonstrating that FK506 rescues Aβ induced deficits in 
transgenic mouse AD models (Hong et al., 2010, Taglialatela et al., 2009, 
Dineley et al., 2007). It suggests that some of the beneficial effects of FK506 on 
AD models may be due to decreases in Aβ generation. Our findings suggest that 
in addition to Aβ induced CaN hyperactivation (Agostinho and C. R. Oliveira 2003, 
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Reese et al., 2008), CaN hyperactivation alters APP processing thereby 
modulating Aβ generation. This scenario creates a potentially pathogenic feed-
forward loop that results in increased amyloidogenic processing and 
neurodegeneration. 
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FIGURES: 
 
 
 
 
 
 
Figure 1-1A. (Michael S. Wolfe, 2009): Regulated Intramembrane Proteolysis 
of APP. APP undergoes proteolysis by α-, β-, and γ- secretases. α -secretase 
and β -secretase produce non-plaque forming p3, while β -secretase and γ -
secretase produce amyloid plaque-forming Aβ. The different regions of the APP 
protein are indicated. 
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Figure 1-1B. (Allinson et al., 2003): Primary sites of cleavage by α, β and γ-
secretases. The grey box indicates the Aβ peptide within APP. Enlargement of 
the Aβ peptide region shows amino acid sequence in single-letter code and 
primary sites of cleavage by α, β and γ-secretases. The Aβ peptide is numbered 
from Asp1, with α-secretase cleaving between Lys16 and Leu17. 
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Figure 1-1C. (Zhang et al., 2007): Identification of APP metabolism 
regulators. AICD based functional screen established in SH-SY5Y APP-Gal4 
cells to identify regulators of APP metabolism whose knockdown alters AICD 
mediated gene transcription (luciferase activity). 
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Figure 1-1D. (Zhang & Khandelwal et al, unpublished data): Calcineurin 
identified as APP metabolism regulator. Knockdown of several genes on 
Chromosome 9 & 10, lead to identification of CaNAβ and CaNB2 as two genes 
that altered AICD mediated luciferase.  Knockdown of APP, Luicferase and use 
of non-coding shRNA’s were used as controls for this screen. 
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Figure 1-1E.  (Human Genome Program, U.S. Department of Energy, Human 
Genome News (v12n1-2). Crystal structure of Calcineurin (CaN). CaN α-
subunit contains a globular phosphatase domain, a helical extension that 
bind the β-subunit, a disordered region not observed in the crystal 
structure, and an autoinhibitory peptide that binds in the phosphatase 
domain’s active site. The α-subunit's intrinsically disordered region, 
containing 95 amino acids, connects the ends of the helical extension 
(residue 374) and the autoinhibitory peptide (residue 470) and includes a 
calmodulin-binding site. This region probably is disordered at least in part 
to allow calmodulin to bind. 
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Figure 1-1F. (Shibasaki et al., 2002): Structure and regulation of CaN:  In the 
regulation of CaN, an increase in the intracellular Ca2+ triggers the binding of 
CaM to CaNA/CaNB heterodimer and dissociated the carboxy-terminal AI 
domain from the catalytic groove. The structural change activates CaNA and is 
reversible. On the other hand, the drug immunophilin complexes such as CsA-
cyclophilin A and FK50-FKBP bind to a CaNA/CaNB heterodimer through the 
latch domain of CaNB and inhibit CaN activity competitively by covering the 
catalytic groove. 
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Figure 1-1G.  (Jin and S. C. Harrison 2002): (A) Ribbon diagrams of the 
Cyp/CsA/CaN ternary complex, (B) and the FKBP/FK506/CaN complex.  CsA 
and FK506 are shown in ball-and-stick representations; CnA is in yellow (with the 
CnB-binding segment in dark yellow); CnB, red; Cyp, green; FKBP, blue; and 
Ca2+ ions, cyan balls. The CaN active-site cleft is indicated with an asterisk. 
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Figure 1-1H. (Robinson and G. M. Bishop 2002): Calcineurin, Aβ  and AD. Left 
hand panel describes how a series of events including CaN activation take place 
in AD, after APP proteolysis is altered and increased Aβ production occurs. Right 
hand panel describes our hypothesis that CaN can regulate APP proteolysis and 
alter levels of Aβ. 
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ABSTRACT: 
Alzheimer’s disease (AD) is a progressive, neurodegenerative brain disorder 
pathologically characterized by the accumulation of amyloid-β peptide (Aβ) and 
intraneuronal neurofibrillary tangles. Aβ peptides are formed as the result of 
proteolytic processing of the β-amyloid precursor protein (APP). Aβ production 
and clearance are considered central events in Alzheimer’s disease (AD) 
pathogenesis. Downstream effects mediated by soluble Aβ aggregates include 
hyperactivation of the Ca2+ and calmodulin-dependent, serine-threonine protein 
phosphatase calcineurin (CaN). Cognitive decline observed in AD models is 
dependent on Aβ generation. CaN has been reported as a potential modulator of 
memory, synaptic plasticity, and neuronal degeneration in brains of AD animal 
models. In the present study we investigate CaN’s ability to regulate APP 
metabolism. Using genetic and pharmacologic manipulation of CaN in SH-SY5Y 
and rat cortical neurons, as well as in a γ-secretase reporter fly line and in a 
transgenic fly AD model, we show that inhibition of CaN activity alters proteolytic 
processing of APP ultimately resulting in decreased Aβ and AICD levels. 
Coinciding with these changes are significant improvements in the Aβ-dependent, 
AD-like behavioral and cognitive deficits observed in our transgenic fly AD model.  
Our results suggest that CaN inhibition may rescue cognitive and 
neurodegenerative effects of Aβ by regulating APP proteolytic processing.   
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Introduction:  
Calcineurin (CaN) is a Ca2+/calmodulin-dependent serine/threonine protein 
phosphatase (Shibasaki et al., 2002) that is highly expressed in the central 
nervous system (CNS). CaN functions as a heterodimer consisting of a 58-64 
kDa catalytic subunit (CaNA) tightly bound to a 19 kDa regulatory subunit (CaNB) 
(Hashimoto et al., 1990). Three isoforms of CaNA (α, β, γ), encoded by separate 
genes (PPP3CA, PPP3CB, and PPP3CC), have been identified and their amino 
acid sequences are highly conserved from yeast to mammals (Shibasaki et al., 
2002). The regulatory subunit, CaNB, contains four Ca2+ binding “EF- hand” 
motifs and has two mammalian isoforms, CaNB1 (PPP3R1) and CaNB2 
(PPP3R2), which are highly conserved. 
     CaN plays fundamental roles in neuronal plasticity and working memory 
(Zeng et al., 2001, Groth et al., 2003). Memory deficits are one of the defining 
characteristics of Alzheimer’s disease (AD). In cellular and animal models of AD, 
upregulation of CaN activity is observed (Agostinho et al., 2008, Dineley et al., 
2007, Mohmmad Abdul et al., 2011). This CaN hyperactivity seems to be the 
result of oligomeric Aβ induced increases in cytosolic Ca2+ concentration 
(Demuro et al., 2010, Reese et al., 2008, Agostinho and C. R. Oliveira 2003). 
CaN activity is involved in Aβ mediated neuronal dysfunction observed in AD 
models and may play an important part in the cognitive deficits observed in AD 
models and patients (Agostinho and C. R. Oliveira 2003, Norris et al., 2005, 
Dineley et al., 2007, Kuchibhotla et al., 2008, Taglialatela et al., 2009, Abdul et 
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al., 2009). Another important connection to AD is the ability of CaN to modulate 
tau phosphorylation status (Rahman et al., 2006, Karch et al., 2013). 
     Given these roles of CaN in AD, it is not surprising that inhibition of CaN by 
FK506 has been shown to ameliorate the neuropathological, morphological, and 
cognitive deficits observed in mouse models of AD (Dineley et al., 2007, 
Taglialatela et al., 2009, Wu et al., 2010, Hong et al., 2010, Rozkalne et al., 
2011). What has not been thoroughly investigated though, is the effect of CaN 
inhibition on Aβ production. Aβ is produced by amyloidogenic proteolytic 
cleavage of APP. To generate Aβ, APP is initially cleaved by β-secretase (BACE) 
to produce sAPPβ and a carboxy terminal fragment (CTF) of 99 amino acids in 
length. This CTF is then cleaved by γ-secretase to produce Aβ and AICD (APP 
intracellular domain) (De Strooper and W. Annaert 2000). Alternatively, non-
amyloidogenic processing can also occur. Here, APP is initially cleaved by α-
secretase (ADAM 9, 10, or 17) to produce sAPPα and a CTF of 83 amino acids 
in length. This shorter CTF is then cleaved by γ-secretase to produce p3 and 
AICD.  
     To determine if APP metabolism is regulated by CaN, we utilized in vitro and 
in vivo models of AD (Guo et al., 2003, Zhang et al., 2007, Chakraborty et al., 
2011). Using knockdown and overexpression of CaNAβ, along with 
pharmacologic inhibition of CaN activity, we observe in vitro changes in APP 
processing and phosphorylation coinciding with decreased Aβ and AICD levels. 
To confirm and extend these results, we utilized two Drosophila models of AD. 
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We observed that CaN inhibition in vivo also alters APP cleavage leading to 
reduced Aβ levels. Aβ-dependent behavioral and cognitive deficits associated 
with these models were also rescued upon CaN inhibition. Therefore, we 
conclude that CaN is a regulator of APP metabolism and modulation of APP 
processing may underlie some of the beneficial effects observed in AD models 
upon CaN inhibition.  
Results:  
Calcineurin knockdown, overexpression, and pharmacological inhibition 
modulate AICD mediated phenotypes in vitro. 
Genome-wide association, linkage, and linkage disequilibrium studies have 
identified the existence of multiple, putative AD risk genes on several human 
chromosomes (Saunders et al., 2003, Blacker et al., 2003, Bertram et al., 2007). 
We consider these genes as positional candidate genes that could function in 
regulating APP metabolism. Therefore, we have undertaken a systematic search 
for regulators of APP metabolism utilizing an APP-Gal4/Gal4-UAS luciferase 
reporter system (Zhang et al., 2007). In this system, production of AICD-Gal4 via 
normal α-, β- and γ-secretase processing leads to transcriptional activation of 
luciferase. We knocked down ~600 genes on chromosomes 9 and 10 and 
identified genes that regulate luciferase activity (Khandelwal, Zhang, et al, 
unpublished data). Using this approach, we identified PPP3CB (CaNAβ) as a 
modulator of AICD-Gal4 mediated transcription. Specifically, we observed that 
PPP3CB knockdown in cells that stably carry this reporter system, SH-SY5Y 
APP Gal4 cells, leads to a significant decrease in AICD-Gal4 mediated luciferase 
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activity when compared to the non-silencing shRNA control (Figure 2-1A). To 
further test whether CaNAβ regulates APP metabolism, CaNAβ was 
overexpressed in the same cell line, and a significant increase in AICD-Gal4 
mediated luciferase activity was observed (Figure 2-1B).  
     CaN phosphatase activity can be pharmacologically inhibited using the 
fungally derived immunosuppressive drug FK506 (Tacrolimus). FK506 is specific 
for CaN and is an FDA approved drug used clinically as an immunosuppressant 
to prevent organ rejection after transplant surgery (Schreiber and G. R. Crabtree 
1992). FK506 must form a complex with an endogenous immunophilin, FKBP12 
(FK506 binding Protein12), to inhibit CaN phosphatase activity (Lam et al., 1995). 
To determine if pharmacological inhibition of CaN activity also alters APP 
metabolism in vitro, SH-SY5Y APP-Gal4 cells were treated with FK506 (100 nM) 
and compared to cells treated with vehicle control (0.1% DMSO). FK506-
mediated CaN inhibition led to a significant decrease in AICD-Gal4 mediated 
luciferase activity (Figure 2-1C).  
Calcineurin inhibition increases APP-CTF & phospho-APP-CTF levels in 
vitro. 
To confirm that these observations were specific to CaN mediated changes in 
APP metabolism rather than non-specific effects of a reporter gene and/or the 
human neuroblastoma cell line, naïve rat primary cortical neurons were treated 
with FK506 and effects on APP processing were monitored. We observed that 
FK506 treatment (3 µM) led to a significant increase in the levels of APP-CTF 
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while not affecting FL-APP levels (Figure 2-2 (A-D)). These effects were dose-
dependent and detectable even with 1 hour of FK506 treatment (data not shown). 
To determine if these FK506 mediated changes in APP-CTF levels were due to 
changes in α- or β-secretase mediated cleavage of APP, we probed conditioned 
media with antibodies for sAPP total and sAPPβ. No changes in the levels of 
either product were observed (Figure 2-2 (B, C & E). We then measured levels of 
secreted Aβ40 and observed a significant reduction in levels of Aβ upon FK506 
treatment (Figure 2-2F). AICD levels were significantly reduced under the same 
conditions (Figure 2-2 (G & H)). Given the increase in APP-CTFs and the 
decrease in Aβ and AICD levels with FK506 treatment, we explored if this altered 
γ-secretase cleavage was limited to APP or could be observed with other γ-
secretase substrates. We treated HEK-293 cells overexpressing NotchΔE with 
FK506 and did not observe a significant change in NICD levels; while treatment 
with a γ-secretase inhibitor resulted in a robust and significant decrease in NICD 
levels (Figure 2-2 (I & J)). 
     Given CaN’s functional role as a phosphatase and the well-studied role of 
APP phosphorylation on it’s own processing, we probed lysates of FK506 treated 
neurons with an APP Thr668 phospho-specific antibody (Ando et al., 1999). We 
observed a robust increase in levels of phosphorylated APP-CTF, but no change 
in phosphorylated FL-APP (Figure 2-2(K & L)). Given the large increase in 
phospho-Thr668 APP-CTFs, we next investigated if FK506 mediated effects on 
APP proteolysis are governed by APP Thr668 phosphorylation. HEK293 cells 
were transiently transfected with either wild-type APP or Thr668Ala APP and 
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treated with FK506. With FK506 treatment of APPwt transfected cells, we 
observed an increase in APP-CTFs. We also saw an increase in APP-CTFs in 
cells transfected with the APP Thr668Ala mutant, but the increase was less 
robust compared to APPwt (Figure 2-2M). However, in these experiments with 
transfected HEK293 cells, we also observed an increase in FL-APPwt and FL-
APP Thr668Ala upon FK506 treatment, which is not observed in neurons. When 
we normalize APP-CTF levels to FL-APP levels we do not observe any FK506 
induced changes in APP-CTF levels for either wild-type or mutant APP (Figure 2-
2N). 
CaN inhibition decreases AICD activity in vivo. 
To determine if CaN inhibition reduces APP-CTF cleavage by γ-secretase in vivo, 
we utilized a Drosophila melanogaster γ-secretase activity reporter line (Guo et 
al., 2003). This reporter relies on flies that carry human APP-CTF fused to Gal4 
(APP-CTF99-Gal4) with expression restricted to the fly eye. Exogenously 
expressed APP-CTF-Gal4 can be cleaved by endogenous γ-secretase activity 
resulting in generation of AICD-Gal4, which translocates to the nucleus and 
transactivate the Gal4/UAS controlled GRIM reporter gene. GRIM induces 
apoptosis, and in this case since its expression is restricted to the photoreceptor 
cells, the morphology of the external eye is disrupted (causing a so called “rough 
eye phenotype”).  
     γ-secretase reporter flies were raised on food containing FK506 or vehicle. 
The eye phenotypes of progeny were scored based on roughness (+ to +++; 
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Figure 2-3 (A - D). Treatment of the reporter flies with FK506 resulted in 
suppression of the rough eye phenotype from γ-secretase reporter flies, 
indicating an in vivo decrease in AICD mediated GRIM activity, and suggesting a 
decrease in APP-CTF γ-secretase cleavage (Figure 2-3E). 
In vivo CaN inhibition decreases Aβ  levels and rescues Aβ-dependent 
phenotypes.  
Given our in vitro data showing decreased Aβ levels in response to FK506 
treatment, we hypothesized that CaN inhibition should decrease Aβ levels and 
rescue Aβ dependent phenotypes observed in transgenic AD models. To test this 
hypothesis, we utilized a Drosophila AD model expressing human APP and 
human BACE genes throughout the developing nervous system (elav; APP; 
BACE; “AD flies”) and treated these flies with FK506 (Chakraborty et al., 2011). 
This model relies on neuronal APP processing to produce Aβ and other 
proteolytic products. Previous characterization of this model has revealed brain 
pathology that is similar to human AD patients, including accumulation of Aβ 
containing puncta in AD fly brains, decreased dendritic and axonal structures in 
areas of the brain used for learning and memory, decreased motor reflexes, and 
importantly the lack of immediate recall memory (Chakraborty et al., 2011).    
     Consistent with our observations in primary neurons, treatment of these AD 
flies with FK506 resulted in a significant increase in brain levels of APP-CTF 
(Figures 2-4 (A & C). While we also observed a small increase in levels of FL-
APP in these fly brains, these effects were not significant (Figure 2-4 (A & C). We 
	   48	  
also probed for changes in APP phosphorylation in these fly brains (Figure 2-4B). 
Qualitative analysis of our results reveals a modest increase in phosphor-Thr668 
APP-CTF levels (Figure 2-4D), however, quantification of these experiments 
revealed no significant differences.  
     Given the observed FK506 induced increase in APP-CTF levels, we 
hypothesized that FK506 treatment should lower brain Aβ load. We observed a 
dose-dependent decrease in levels of Aβ40 and Aβ42 in the brains of AD flies 
treated with FK506 (Table 2-1). This decrease in Aβ load led us to investigate the 
other Aβ related pathologies observed in this AD model (Chakraborty et al., 
2011). Specifically, we assessed amyloid plaque load, neuroanatomy, motor 
reflex behavior, learning behavior, and immediate recall memory. 
     To determine if pharmacological inhibition of CaN effects Aβ aggregation, Aβ 
puncta in fly brains were quantified using immunofluorescence (Chakraborty et 
al., 2011). In AD flies treated with FK506, we observed significantly fewer Aβ 
puncta (Figures 2-5 (A-D)). To confirm that the 6E10 puncta we observed are 
indeed amyloid, we stained brains with X-34, a fluorescent Congo red derivative, 
and observed a similar decrease in amyloid puncta in FK506 treated flies (data 
not shown).  
     The Drosophila mushroom bodies are bundles of axons emanating from 
neurons involved in learning and memory behavior (Heisenberg et al., 1985, 
McBride et al., 1999). The surface areas of these structures are significantly 
decreased in AD flies compared to control flies; this reduction has previously 
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been rescued by treatment with γ-secretase inhibitor (Chakraborty et al., 2011). 
Treatment of AD flies with FK506 results in rescue of the reduced surface area 
size from key mushroom body neuron regions compared to vehicle treated 
control flies (Figure 2-5E). Specifically, the kenyon cells (cell soma), calyx 
(dendritic structures/fields), and lobes (axonal structures/bundles) of the 
mushroom body structures of FK506 treated AD flies display significant 
improvement (Figure 2-5F). In normal flies, these same neuroanatomical regions 
were unaffected by FK506 treatment (Figure 2-5G), suggesting that FK506 
specifically rescues Aβ-mediated neuroanatomical deficits.  
     Having observed marked improvements in neuroanatomical and 
neuropathological deficits of this AD model when CaN is inhibited, we tested the 
ability of FK506 treatment to rescue CNS function. Initially, CNS function was 
tested by assessing broad motor reflex function. The negative geotaxis climbing 
assay assesses the reflexive climbing behavior of flies in response to a 
mechanical stimulus (Iijima et al., 2004, Le Bourg and F. A. Lints 1992). By 
assaying the fly’s ability to climb to the top of a vial in a set time period, we were 
able to assess broad nervous system function of reflex behavior in AD model 
flies treated with FK506. In normal flies, FK506 treatment did not alter this 
behavior (Figure 2-6A). However, AD flies treated with FK506 showed 
significantly improved climbing ability (Figure 2-6B) that was comparable to 
control flies in the initial 11 days of assessment.  
     Finally, we assessed CNS function by measuring learning and memory. Using 
the conditioned courtship suppression assay (measured by courtship index (CI)), 
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we have previously shown that AD flies displayed normal learning (evidenced by 
decreased CI in the last 10 minutes of a 1 hour training period compared to the 
first 10 minutes), but defective immediate recall memory (2 minute memory, 
evidenced by no significant difference in CI in control trained flies compared to 
trained flies) (Siegel and J. C. Hall 1979, Chakraborty et al., 2011). Treatment of 
AD flies with vehicle or FK506 resulted in a significant reduction in CI during the 
last ten minutes of the one-hour training period (Figure 2-6C), indicating proper 
learning for both treatment conditions. As previously reported (Chakraborty et al., 
2011), trained AD flies treated with vehicle do not show a significant decrease in 
CI compared to control trained, age matched AD flies (Figure 2-6C), indicating 
that they have no memory of this training even though these flies are capable of 
learning during training. Trained AD flies raised on FK506 showed a significant 
decrease in CI compared to control trained, age matched AD flies (Figure 2-6D) 
indicating that FK506 treatment rescues the memory defect observed in AD flies. 
 
Discussion: 
Our study demonstrates that inhibition of CaN regulates APP processing in vitro 
and in vivo. We observed that CaNAβ knockdown and FK506 treatment 
decreased AICD mediated reporter gene expression in human SH-SY5Y cells 
and in γ-secretase reporter flies, while CaNAβ over-expression increased 
reporter expression in human SH-SY5Y cells. In rat primary cortical neurons, 
FK506 treatment increased levels of total and phospho-Thr668 APP-CTFs and 
reduced Aβ and AICD levels without altering FL-APP, sAPP total, sAPPβ and 
phospho-Thr668 FL-APP levels. These results suggest that inhibition of CaN 
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phosphatase activity decreases the amount of APP-CTF’s undergoing cleavage 
by γ-secretase. This decrease in γ-secretase cleavage seems to be APP specific 
since no changes in another γ-secretase substrate, NotchΔE, were observed. 
Given these anti-amyloidogenic effects induced by FK506 in neurons, we tested 
whether FK506 altered in vivo APP processing in a similar fashion. Using a 
Drosophila AD model, we inhibited CaN using FK506 and observed increased 
APP-CTFs and decreased Aβ levels. Additionally, the Aβ induced 
neuroanatomical and memory deficits previously observed in this AD model were 
rescued upon administration of FK506. Results from our study suggest CaN 
regulates APP cleavage by modulating the proportion of APP-CTFs undergoing 
γ-secretase cleavage. 
     CaN has been previously identified as a candidate gene that could play a role 
in AD pathogenesis (Taguchi et al., 2005, Augustin et al., 2011, Twine et al., 
2011). Several research groups have reported that Aβ activates CaN and its 
downstream signaling pathways. Specifically, application of oligomeric Aβ 
species to cultured cells leads to a rapid and sustained rise in Ca2+ levels along 
with an increase in CaN activity (Wu et al., 2010, Reese et al., 2008). 
Furthermore, in vitro evidence indicates that Aβ induces neuronal apoptosis 
through a CaN-dependent mechanism (Agostinho and C. R. Oliveira 2003, 
Reese et al., 2008). In the Tg2576 AD mouse model, high CaN activity has been 
reported in the CNS and treatment with FK506 improves memory function, 
indicating that CaN activity is mediating aspects of Aβ induced cognitive decline 
(Dineley et al., 2007, Taglialatela et al., 2009) Similar findings were observed in 
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APP/PS1 mice, where FK506 treatment significantly reduced Aβ burden in the 
absence of changes in β- or γ-secretase activity (Hong et al., 2010).  
     While we observe similar decreases in Aβ levels and improved cognitive 
function in AD models treated with FK506, our study differs from these other 
studies because it demonstrates that CaN modulates APP processing. 
Greengard and colleagues demonstrated that CaN regulates Aβ formation 
(Desdouits et al., 1996) in cell-free membrane extracts, however there has been 
no demonstration, to our knowledge, that CaN regulates APP processing in 
neurons or in living organisms. In addition to decreased Aβ levels, we observe 
decreased AICD levels and increased APP-CTF levels. Similar changes are 
observed when these in vivo AD models are treated with L-685,458, an inhibitor 
of γ-secretase activity (Chakraborty et al., 2011). These results imply that FK506 
mediated inhibition of CaN is regulating γ-secretase mediated cleavage of APP-
CTFs. To explore this possibility, we investigated the effect of CaN inhibition on 
Notch cleavage, another substrate of γ-secretase.  Unlike L-685,458 treatment, 
FK506 treatment did not alter NICD levels, suggesting that the mechanism by 
which FK506 is regulating APP proteolysis does not involve a general inhibition 
of γ-secretase activity.   
     Given that CaN is a serine/threonine phosphatase, we set out to determine 
the role of APP phosphorylation in the FK506-induced changes we observe. The 
role of Thr668 phosphorylation on APP processing is controversial with reports 
concluding that Thr668 phosphorylation has increased, decreased, or has no 
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effect on Aβ levels(Sano et al., 2006, Lee et al., 2003, Vingtdeux et al., 2005, 
Feyt et al., 2007)We observed that FK506 treatment of neurons resulted in 
increased phospho-Thr668 APP-CTFs levels. This increase could drive APP 
processing changes or could be a consequence of APP processing changes. To 
further explore these possibilities, we treated HEK-293 cells transfected with 
wild-type or Thr668Ala APP with FK506. This treatment resulted in a modest 
increase in APP-Thr668Ala-CTFs levels and a more robust increase in APP-CTF 
levels. Unlike FK506 treatment of neurons, however, treatment of these 
transfected HEK293 cells resulted in an increase in FL-APP. Therefore when 
quantifying the effect of FK506 on these cells we do not observe a significant 
increase in the ratio of APP-CTF to FL-APP for the wild-type or mutant APP 
constructs. These results differ from the changes we observed on endogenous 
APP-CTFs in neurons and are most easily explained by the inherent differences 
between APP exogenously expressed in HEK293 cells and endogenous 
expression of APP in primary neurons. This may be particularly true for CaN 
mediated phenomena, since CaN is a calcium regulated phosphatase and 
neurons tightly regulate Ca2+ signaling given the large number of Ca2+ 
dependent events that occur within neurons (Wu et al., 2010). Given these 
observations, we cannot conclusively determine the role of Thr668 in FK506 
induced changes in APP processing. 
     The effects we observe in neurons are generally recapitulated in FK506 
treated AD flies. We observe increased levels of APP-CTFs along with 
decreased Aβ levels, decreased AICD-mediated reporter gene expression, and 
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no significant changes in FL-APP. Unlike neurons, however, the increase 
observed in AD fly phospho-Thr668 APP-CTFs did not reach statistical 
significance. One reason for this discrepancy may be the cell type heterogeneity 
of whole Drosophila brain compared to a relatively homogeneous culture of 
cortical neurons. It is also is possible that different cell types within fly brain have 
different responses to FK506 leading to differences in APP phosphorylation 
between cell types. The altered APP processing and phosphorylation observed in 
HEK293 cells in response to FK506, compared to neurons, could be evidence of 
such cell type specificity. Alternatively, Thr668 phosphorylation may not be 
involved in mediating the FK506 induced changes in AD fly brains. Finally, we 
observe robust improvement in the Aβ induced deficits in mushroom body 
neuroanatomy and memory upon FK506 treatment. The changes we observe in 
APP-CTFs and Aβ levels lead us to suggest that changes in APP processing are 
responsible for the improvements seen in the AD flies. It is possible that Aβ 
degradation could be increased by FK506 treatment. In fact, Hong et al observed 
that the FK506 induced improvements in APP/PS1 AD mouse model 
corresponded to increased levels of the Aβ degrading protease, MMP9, in 
astrocytes (Hong et al., 2010).  
     Taken together, our findings demonstrate that pharmacological inhibition of 
CaN using FK506 leads to altered APP proteolysis resulting in decreased levels 
of Aβ and AICD. These changes coincide with a rescue of Aβ-dependent  
cognitive and neuroanatomical deficits. Decreased Aβ levels seem to be due to 
decreased APP-CTF cleavage by γ−secretase. This decrease in γ−secretase 
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cleavage seems to be specific to APP since Notch cleavage wasn’t affected. 
APP cleavage by γ−secretase could be specifically modulated by de-
phosphorylation of APP at Thr 668 or other Ser/Thr residues. In addition, FK506 
may alter phosphorylation of one or more of the γ−secretase components leading 
to changes in substrate specificity or activity. FK506 treatment could also alter 
APP subcellular localization / trafficking, which is an important determinant of 
APP proteolysis. Such changes could regulate the availability of APP-CTFs to 
γ−secretase, or vice versa. The exact mechanism involved is under investigation.  
     To our knowledge our study is the first to directly demonstrate the ability of 
CaN to regulate neuronal APP processing.  Overall our results support previous 
work demonstrating that FK506 rescues Aβ induced deficits in transgenic mouse 
AD models (Hong et al., 2010, Taglialatela et al., 2009, Dineley et al., 2007). It 
suggests that some of the beneficial effects of FK506 on AD models may be due 
to decreases in Aβ generation. Our findings suggest that in addition to Aβ 
induced CaN hyperactivation (Agostinho and C. R. Oliveira 2003, Reese et al., 
2008), CaN hyperactivation alters APP processing thereby modulating Aβ 
generation. This scenario creates a potentially pathogenic feed-forward loop that 
results in increased amyloidogenic processing and neurodegeneration.  
Experimental Procedures:  
Plasmids:  
APP-Gal4, Gal4-UAS-luciferase plasmids were kindly provided from Dr. Thomas 
Südhof (Cao and T. C. Sudhof 2001). CaNAβ (PPP3CB) overexpression plasmid 
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was purchased from Open Biosystems. shRNA constructs targeting APP, 
Luciferase, CaNAβ, along with non-silencing shRNA were also obtained from 
Open Biosystems, Inc. A Renilla luciferase reporter plasmid (pRLSV40) was 
utilized to normalize for transfection efficiency (Promega). The APP Thr668Ala 
mutant over-expression plasmid was kindly provided by Dr. Mikko Hiltunen.  
Antibodies: 
Primary antibodies utilized were: C1/6.1 monoclonal antibody recognizing the C- 
terminus of APP (Paul M. Mathews), sAPPβ specific monoclonal antibody 
(BAWT, Stefan Lichtenthaler), an anti-APP monoclonal antibody was used to 
detect sAPP total levels (22C11, Millipore), a monoclonal anti-β-Actin antibody 
(A5441, Sigma Aldrich, Inc), a polyclonal antibody that recognizes APP 
phosphorylated at Thr668(D90B8; Cell Signaling Technologies). NotchΔE and 
NICD were detected using an anti-Myc antibody and a cleaved Notch 1(Val 
1744) antibody (D3B8; Cell Signaling Technologies), respectively. Western blot 
secondary antibodies used were goat anti-Rabbit IR-Dye800 CW (LiCor Inc.) 
and/or goat anti-Mouse IR Dye 680 (LiCor Inc.). Secondary antibodies used for 
immunohistochemistry on fly brains were goat anti-rabbit TRITC (111-116-144), 
goat anti-rabbit Cy5 (111-176-144), and goat anti-mouse Cy5 (115-176-072), all 
purchased from Jackson ImmunoResearch. 
Cell culture:  
SH-SY5Y cells were purchased from the American Type Culture Collection 
(Manassas, VA). These cell lines were cultured in Dulbecco’s modified Eagle's 
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medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 
100 units/ml penicillin, and 100 µg/ml streptomycin. SH-SY5Y cells that stably 
express APP-Gal4 and the Gal4-UAS-luciferase reporter construct (referred to as 
“SHY5Y-APP-Gal4 cells“) were maintained with media containing 200 µg/ml 
G418 (Zhang et al., 2007).  All animals used to generate primary neuronal culture 
were used in accordance with animal protocols approved by the Institutional 
Animal Care and Use Committee (Protocol # 19787). Primary mixed cell cultures 
were prepared from the cerebral cortices of 1-day-old (P1) neonatal Sprague 
Dawley rats. Briefly, cortices were dissected, treated with papain (100 Units for 
15 minutes at 37°C; Worthington Biochemicals), and then treated with trypsin 
inhibitor (15 minutes at 37°C; Sigma-Aldrich). The tissue was washed with fresh 
Neurobasal medium supplemented with B-27, 2 mM L-glutamine, 100 Units/ml 
penicillin, and 100µg/ml streptomycin.  Cortices were triturated, centrifuged at 
1000 rpm for 10 minutes then resuspended in the fresh, complete Neurobasal 
media described above. 2 X 106 cells were plated into each well of a 6-well plate; 
these plates were coated overnight with poly-DL-lysine (50 µg/ml; Sigma-Aldrich) 
at 37°C in 5% CO2. These cortical neurons were cultured for six days in vitro 
(DIV 6) at which time drugs were administered. Drug treatments were performed 
in complete Neurobasal medium.  
RNAi & Overexpression: 
For the RNAi experiments, we followed published procedures (Zhang et al., 
2007). We utilized shRNAs targeting APP and Luciferase as positive controls 
(Open Biosystems). shRNAs targeting CaNAβ (PPP3CB) (Open Biosystems)  
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were used to target CaN catalytic subunit. SH-SY5Y-APP-Gal4 cells were also 
transiently transfected with CaNAβ overexpression constructs along with Renilla 
luciferase plasmid pRLSV40 (Promega), a control for transfection efficiency.  24 
hours post-transfection, cell lysates were collected in Glo lysis buffer (Promega) 
following the manufacturer’s instructions.  
Pharmacologic Inhibition of CaN: 
For in vitro inhibition of CaN, FK506 (Sigma-Aldrich) was dissolved in DMSO 
(99.9%) to obtain a final concentration of 10 mM. This stock was further diluted in 
complete media to obtain final FK506 concentrations of 100 nM or 3 µM. The 
final DMSO concentration was 0.1%, therefore 0.1% DMSO was used for the 
vehicle control. To treat flies with FK506, the drug was dissolved in DMSO 
(99.9%) to a final concentration of 0.1 mM and was further dissolved in 
Drosophila food to obtain final concentrations of 10 nM and 100 nM.  
Luciferase assay: 
For luciferase assays, SH-SY5Y APP-Gal4 cells stably expressing shRNA 
constructs or CaN overexpression construct were washed twice with cold PBS 
and lysed with 100 ml of Glo lysis buffer (Promega). Similar procedure was also 
carried out for SH-SY5Y APP-Gal4 cells treated with FK506. The assay was 
performed as described previously (Zhang et al., 2007). Dual luciferase assays 
were performed for the cells transiently transfected with CaNAβ, overexpression 
construct and with pRL-SV40, which constitutively overexpresses Renilla 
luciferase following the manufacturers instruction (Promega).  
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Western Blot Analysis:  
Fly heads were collected six days after eclosion from respective genotypes 
and/or treatments and lysed in RIPA buffer (3 µL per head; 50 mM Tris, 150 mM 
NaCl, 1% SDS, 1% NP-40, 0.5% deoxycholate, pH 8.0 and protease and 
phosphatase inhibitor cocktail (ThermoFisher)). The cell lysates of primary 
cortical neurons were generated using RIPA and determining the protein 
concentration. Samples for Western blot were prepared using the 4x NuPage 
LDS sample buffer (Invitrogen) containing 0.2% β-Mercaptoethanol (Sigma 
Aldrich). A volume equal to 15-20 fly heads or 30-50 µg of the protein from cell 
lysates was loaded into each well of NuPAGE 4-12% Bis Tris gel (Invitrogen). A 
molecular weight ladder (Two color protein standard, 928-40001, Li-COR) was 
always run along with the experimental samples. Densitometry of individual 
bands were quantified using the software (ODYSSEY Infrared imaging system, 
Application software) and normalized to the densitometry of β-actin. All Western 
blot experiments were performed in triplicates.  
Immunofluorescence: 
The brains of adult flies raised on different drug treatments were dissected, fixed 
and prepared as described (Guo et al., 2003, Chakraborty et al., 2011). Six days 
after eclosion, brains were dissected directly in fixative (4% paraformaldehyde), 
washed and exposed to the primary antibodies described above. Brains were 
whole mounted in vectashield (Vector Labs, H-1000). All fluorescent imaging was 
done using an Olympus FluoView FV1000 laser scanning confocal microscope 
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and using the antibodies described above.  Image J (http://rsbweb.nih.gov/ij/) 
was used to quantify images.  
Neuroanatomical Analysis:  
To assess changes in Drosophila neuroanatomy, we measured the surface area 
of kenyon cells, calyx, and lobes, using Drosophila that express a membrane 
tagged form of GFP (CD8-GFP) in the nervous system under UAS control. elav-
Gal4, UAS:CD8-GFP; UAS:hAPP; UAS:hBACE heterozygous females raised on 
different drug concentrations, were dissected on Day 6 and serial confocal 
microscope sections were obtained at 200X magnification. Kenyon cells, calyx, 
lobes were stacked and pixels were measured using Image J 
(http://rsbweb.nih.gov/ij/). Four brains were analyzed for each genotype. To count 
6E10 positive puncta, brains were fully optically sectioned by confocal 
microscope at 200X magnification. Puncta were counted in each brain section 
and the numbers were averaged out for each genotype.  
 
Aβ ELISA and AICD detection: 
In AD flies, Aβ40 and Aβ42 levels were determined using commercially available 
human Aβ specific ELISA kits (BetaMark, Covance, Dedham, MA) according to 
the manufacturer’s instructions. Lysates were obtained by homogenizing heads 
of AD flies raised on food containing FK506 or 0.1% DMSO. For each treatment 
tested, homogenates from 100 fly heads were used for each drug concentration. 
These heads were mechanically homogenized and then centrifuged for 20 min at 
14,000 rpm. After centrifugation the supernatant was collected and stored in -80° 
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C until needed.  In rat cortical neurons, secreted Aβ40 levels were detected using 
commercially available Human/Rat βAmyloid (40) ELISA Kit Wako (Wako 
Catalog #294-62501, 96 tests) according to the manufacturer’s instructions. 
     The in vitro AICD generation assay was performed as previously described 
with minor changes (Marambaud et al., 2003). Specifically, membranes from 
primary cortical neurons were resuspended in 25 µL of assay buffer (150 mM 
sodium citrate, [pH 6.4], 2 mM 1, 10-phenanthroline and protease inhibitor 
cocktail (ThermoFisher)) in the presence of 3 µM γ-secretase inhibitor (L-685, 
458), 3 µM FK506, or vehicle (DMSO) at 37°C for 18 hr. Control samples were 
kept at 4°C. Membrane extracts were cleared by ultracentrifugation for 1 h at 
100,000 × g at 4°C. Samples were analyzed by Western blot analysis on 10–
20% Tris–Tricine gels (Invitrogen) and probed with C1/6.1. 
Drosophila Stocks and Genetics: 
All crosses and stocks were maintained at 25° C. Normal food and fly food 
containing pharmacological agents was prepared as described previously 
(Chakraborty et al., 2011). For experiments utilizing the APP-Gal4; UAS-GRIM 
system, the effects on adult fly eye morphology were recorded by photographing 
the eyes (SPOT digital camera mounted to a Leica Mz 125 stereomicroscope). 
Using these images, eye phenotype was scored (+ to +++) for effects on eye 
morphology. “+” is a rough eye, where at least one-half of the eye field is wild 
type. “++” is a rough eye where more than one-half of the eye is rough, usually 
affecting the whole eye, but not always. “+++” is a strong rough eye where the 
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entire eye is affected, and there is a strong loss of pigment in the posterior one-
half of the eye. To study the effect of the pharmacological drug FK506 on GMR-
APP-Gal4, UAS:GRIM / Cyo  flies, they were outcrossed to  w1118 flies on either 
the drug food (FK506) or the vehicle (0.1% DMSO) and progeny flies were 
scored for the eye morphology 24 hours after eclosion.   
     P{GawB}elavC155 (Bloomington stock #458) was used to cause pan-neuronal 
expression of the transgenes and is abbreviated in the text as elav. 
P{GawB}elavC155, P{UAS-mCD8::GFP.L}LL4, P{hsFLP}1, w - (Bloomington stock 
#5146) was used to cause pan-neuronal expression of transgenes, including the 
membrane-bound GFP and is abbreviated elav-Gal4, UAS:CD8-
GFP. Bloomington stock w1118 (#3605; Bloomington Stock Center, 
http://flybase.bio.indiana.edu/) was used to generate outcrossed controls and is 
referred to as w- in the text.  
Behavioral testing and training: 
Flies were maintained in a 12:12 light: dark cycle at 25° C and 60% 
humidity.  Flies were collected and the assay was performed as described 
previously (Chakraborty et al., 2011). For learning and memory assays, 16-20 
flies were assayed for each treatment. The total time that a male performed 
courtship activity was measured and scored. The Courtship Index (CI) was 
calculated as the total time observed performing courting behavior divided by the 
total time assayed, as described. For climbing assays, 100-150 flies were 
assayed for each treatment. The average climbing index for days 1-11 and days 
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12-21 was binned. 
Statistical Analysis: 
Values in the text and figures are presented as means ± standard errors of at 
least three independent experiments. Equal variance or separate variance two-
sample student’s t-test were used, as appropriate, to compare two groups. “*” 
indicates p < 0.05, “**” indicates p < 0.01, and “***” indicates p < 0.001. “n.s.” 
indicates p-values greater than 0.05. For our in vivo studies, to determine if there 
was a statistically significant change in phenotype relative to wild type we 
performed a G-test of homogeneity and reported the p-values. To analyze 
behavioral-testing data, a one-way ANOVA and Tukey’s post-hoc analysis was 
used to determine significant difference between DMSO control and treatment 
groups.  All statistics were performed using PASWStatistics version 20.0 or Excel. 
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Table Legend: 
Table 2-1. Calcineurin inhibition in AD flies decreases Aβ levels. 
Aβ levels in AD fly brain homogenates were assessed using isoform specific 
ELISA. ELISA was performed in triplicates from a sample consisting of 
population of flies including several independent generations. “*”: p < 0.05, “**”: p 
< 0.01, and “***” :p < 0.001 (Student’s t-test). 
Figure Legends: 
Figure 2-1. Calcineurin regulates AICD-mediated luciferase activity.  
SH-SY5Y APP-Gal4 cells expressing APP-Gal4 and Gal4-UAS luciferase were 
used to monitor AICD-Gal4 mediated luciferase activity. Luciferase activity was 
measured in response to (A) Knockdown of CaNAβ, APP, Luc or control, (B) 
CaNAβ overexpression, (C) FK506 (100 nM for 24 hours) or vehicle treatment. 
Values are means ± standard errors of 3 independent experiments.  “*”: p < 0.05, 
and “***” :p < 0.001 (Student’s t-test). 
Figure 2-2. Calcineurin inhibition alters APP processing and 
phosphorylation but not Notch processing.   
Rat primary cortical neuronal cultures (DIV 6) were treated with FK506 (3 µM for 
24 hours). Representative Western blots of: (A) cell lysates probed with a C-
terminal anti-APP antibody (C1/6.1) and β-Actin which is used as the loading 
control, (B) conditioned media probed with N-terminal anti-APP antibody (22C11), 
and (C) conditioned media probed with a sAPP-β specific antibody (BAWT). (D) 
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Quantification of cell lysate Western blot data. (E) Quantification of conditioned 
media Western blot data. (F) Secreted, relative Aβ40 levels were measured using 
ELISA. (G) Representative Western blot of neuronal membrane generated AICD 
probed with C1/6.1. (H) Quantification of the AICD Western blot data. (I) 
Representative Western blot of HEK293 cells overexpressing NotchΔE probed 
with an anti-Myc antibody to detected NotchΔE, anti-NICD, and β-Actin, which is 
used as the loading control. (J) Quantification of the NotchΔE Western blot data. 
(K) Representative Western blot of rat primary neuron cell lysates and probed 
with an anti-phospho Thr668 APP antibody. (L) Quantification of the phospho-
Thr668 APP Western blot. (M) Representative Western blot of HEK293 cells 
overexpressing wild type or T668A APP probed with C1/6.1, anti-phospho-
Thr668 APP, and β-Actin. (N) Quantification of wild-type and T668A 
overexpression Western blot data. Values are means ± standard errors of 3 
independent experiments. “*”: p < 0.05, “***” :p < 0.001 and “n.s.” : p-values > 
0.05 (Student’s t-test). 
Figure 2-3. Calcineurin inhibition regulates AICD-Gal4 mediated reporter 
gene expression in vivo.  
Treatment of GMR-APP-Gal4, UAS:GRIM flies (γ-secretase reporter flies) with 
FK506. (A-D) The eye phenotypes of progeny were scored based on a 
roughness scale (+ to +++). (E) Quantitative analysis of eye phenotype 
distribution. A total of 87 and 53 flies were scored for vehicle and FK506 
treatment groups respectively. “***” :p < 0.001 (G-test of homogeneity). 
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Figure 2-4. Calcineurin inhibition in AD flies increases APP-CTF levels.  
Representative Western blots of fly heads from AD flies treated with either 
vehicle or FK506 and probed with (A) C1/6.1, β-Actin (B) anti-phospho Thr668 
APP, and β-Actin. (C) Quantification of the total APP Western blots. (D) 
Quantification of Phospho-Thr668 FL-APP Western blot. Values are means ± 
standard errors of 3 independent experiments. “*”: p < 0.05, “n.s.” : p > 0.05 
(Student’s t-test). 
Figure 2-5. Calcineurin inhibition of AD flies decreases Aβ and amyloid 
levels in CNS.  
Representative confocal microscopy stacked sections of whole adult 6-day old fly 
brains stained with an anti-Aβ antibody (6E10): (A) a representative control fly, 
and a representative brains from AD flies raised on (B) vehicle or (C) FK506. (D) 
Quantification of panels A, B and C. (E) Representative confocal images of 
mushroom body neuroanatomy in: control (elav-CD8-GFP; +; + heterozygous) fly 
brain (top row) and AD (elav-CD8-GFP; APP; BACE heterozygous) fly brain 
raised on vehicle (middle row) or these same flies raised on 100 nM FK506 
(bottom row). Kenyon cells (KC) represent KC cell soma, Calyx represents KC 
dendritic structures, Lobes represent KC axonal structures. (F-G)  Quantification 
of mushroom body surface area for different treatments. Mean surface area, 
where error bars represent standard error of the means, for 3-5 brains per 
treatment. For panels A, B, and C the scale bar indicates 100 µm. For panel E 
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the scale bar indicated 20 µm. “*”: p < 0.05, “**”: p < 0.01 and “n.s.” : p-values > 
0.05 (Student’s t-test). 
Figure 2-6. Calcineurin inhibition of AD flies improves behavioral and 
cognitive deficits.  
(A) Quantification of climbing behavior for control flies from days 1-11.  (B) 
Comparison of climbing behavior between the control and AD flies. (C) Courtship 
Index measured during the first 10 minutes and last 10 minutes of the courtship 
suppression assay-training phase. (D) Courtside Index measured 0-2 minutes 
post-training of control trained flies and trained flies. “*”: p < 0.05, “**”: p < 0.01, 
and “***” :p < 0.001. “n.s.” : p > 0.05; one-way ANOVA and Tukey’s post-hoc 
analysis.  
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 pg / mL 
Sample Aβ40 Aβ42 
Vehicle 44.0 ± 2.1 5.6 ± 0.8 
FK506 (10 nM) 13.5 ± 0.3*** 3.5 ± 0.1* 
FK506 (100 nM) 4.61 ± 1.29*** 0.30 ± 0.47** 
 
Table 2-1 Calcineurin inhibition in AD flies decreases Aβ levels. 
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FIGURES: 
 
 
 
 
Figure 2-1A. Calcineurin knockdown decreases AICD-mediated luciferase 
activity.  
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Figure 2-1B. Calcineurin overexpression increases AICD-mediated 
luciferase activity.  
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Figure 2-1C. Calcineurin inhibition decreases AICD-mediated luciferase 
activity. 
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 Figure 2-2 (A, B, & C). Calcineurin inhibition alters APP processing. 
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Figure 2D. Calcineurin inhibition increases APP-CTF levels & does not alter 
FL-APP levels. 
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Figure 2-2E. Calcineurin inhibition does not alter sAPP-Total & s-
APPβ  levels 
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Figure 2-2F. Calcineurin inhibition decreases Aβ40 levels. 
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Figure 2-2G. Calcineurin inhibition decreases AICD levels. 
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Figure 2-2H. Calcineurin inhibition decreases AICD levels 
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Figure 2-2I. Calcineurin inhibition does not alter Notch processing. 
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Figure 2-2J. Calcineurin inhibition does not alter Notch processing. 
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Figure 2-2K. Calcineurin inhibition increases APP-CTF Thr668 PO4-   & does 
not alter FL-APP Thr668 PO4-. 
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Figure 2-2L. Calcineurin inhibition increases APP-CTF Thr668 PO4-   & does 
not alter FL-APP Thr668 PO4-. 
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Figure 2-2M. Calcineurin inhibition alters processing of WT-APP and 
Thr668 Ala mutant of APP. 
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Figure 2-2N. Calcineurin inhibition alters processing of WT-APP and Thr668 
Ala mutant of APP. 
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Figure 2-3 (A, B, & C). Calcineurin inhibition decreases AICD-Gal4 mediated 
reporter gene expression in vivo.  
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Figure 2-3E. Calcineurin inhibition decreases AICD-Gal4 mediated reporter 
gene expression in vivo.  
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Figure 2-4A. Calcineurin inhibition in AD flies increases APP-CTF levels & 
does not alter FL-APP levels.  
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Figure 2-4B. Calcineurin inhibition in AD flies alters APP-CTF Thr668 PO4- 
levels.  
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Figure 2-4C. Calcineurin inhibition in AD flies increases APP-CTF levels.  
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Figure 2-4D. Calcineurin inhibition in AD flies alters APP-CTF Thr668 PO4- 
levels.  
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Figure 2-5 (A, B, & C). Calcineurin inhibition of AD flies decreases Aβ and 
amyloid levels in CNS.  
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Figure 2-5D. Calcineurin inhibition of AD flies decreases Aβ and amyloid 
levels in CNS.  
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Figure 2-5E. Calcineurin inhibition does not alter neuroanatomical 
structures in the control fly brains. 
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Figure 2-5F. Calcineurin inhibition of AD flies rescues neuroanatomical 
deficits. 
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Figure 2-5G. Calcineurin inhibition of AD flies rescues neuroanatomical 
deficits. 
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Figure 2-6A. Calcineurin inhibition of control flies does not alter behavioral 
deficits.  
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Figure 2-6B. Calcineurin inhibition of AD flies improves behavioral deficits.  
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Figure 2-6C. Calcineurin inhibition of AD flies improves cognitive deficits.  
 
 
 
 
 
 
  
	   98	  
 
 
 
 
Figure 2-6D. Calcineurin inhibition of AD flies improves cognitive deficits.  
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Abstract: 
Alzheimer’s disease (AD) is a complex neurodegenerative disease, 
pathologically characterized by the accumulation of β-amyloid peptide (Aβ) and 
intraneuronal neurofibrillary tangles. Production of the Aβ peptide by the 
regulated intra-membrane proteolysis of the β-amyloid precursor protein (APP), 
is a central event in AD. Cognitive decline observed in AD models is dependent 
on Aβ generation. One of the downstream effects mediated by soluble Aβ 
oligomers includes the hyperactivation of calcineurin (CaN), a Ca2+ and 
calmodulin-dependent, serine-threonine protein phosphatase. CaN is one of the 
major phosphatase associated with cognitive and neurodegenerative effects of 
Aβ.  A specific isoform of CaN, CaNAβ, is one of the most up-regulated mRNAs 
in brains of early stage AD patients. While Aβ’s ability to activate CaN has been 
well studied, not much is known about how increased levels of CaN in AD brain 
can contribute towards Aβ generation.  In this study we specifically investigate if 
increased levels of CaNAβ regulate APP metabolism. Our results demonstrate 
that increased CaNAβ expression leads to increased APP levels and increased 
proteolytic products of APP, including Aβ. This data suggests that upregulation of 
CaN levels could contribute to neurodegeneration observed in AD by increasing 
levels of Aβ, potentially forming a pathogenic feed forward loop.  
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Introduction: 
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder 
characterized by global cognitive decline involving memory, orientation, judgment, 
and reasoning  (Tanzi and L. Bertram 2005). The characteristic patho-biological 
hallmarks of AD include the presence of neurofibrillary tangles, senile plaques, 
and massive loss of neurons, primarily in cerebral cortex and hippocampus in the 
brain  (Selkoe 2003). The neurofibrillary tangles are paired helical filaments 
containing the hyperphosphorylated form of the microtubule binding protein Tau. 
Senile plaques are extracellular deposits composed of β-amyloid (Aβ) peptide  
(Selkoe 2003). The Aβ peptides are generated by proteolytic processing of the 
large, type-I transmembrane protein, β-amyloid precursor protein (APP)  (Shoji et 
al., 1992). Aβ is produced via the regulated intramembraneous proteolysis of 
APP. APP is initially cleaved by β-secretase (BACE) to produce sAPPβ and a 
carboxy terminal fragment of 99 amino acids (CTF-99). This CTF is then cleaved 
by γ-secretase to produce Aβ and AICD (APP intracellular domain) (De Strooper 
and W. Annaert 2000). Alternatively, non-amyloidogenic processing can also 
occur. Here APP is initially cleaved by α-secretase (ADAM 9, 10, 17) to produce 
sAPPα and a CTF of 83 amino acids in length (CTF-83). This shorter CTF is then 
cleaved by γ-secretase to produce p3 and AICD. Because Aβ is generated as 
part of the normal APP processing, deregulation of APP processing can alter the 
levels of Aβ being produced. Excessive production and accumulation of the Aβ 
peptide plays a fundamental role in AD pathology. Therefore, APP proteolysis is 
considered a central event in the development of AD. 
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     Aβ’s ability to activate Calcineurin (CaN), a member of the serine/threonine 
protein phosphatase family, has been well studied (Kuchibhotla et al., 2008, Wu 
et al., 2010, Loo et al., 1993). Specifically, increased Aβ levels  perturb 
intracellular Ca2+ levels which, in turn, leads to CaN hyperactivity. This 
Aβ−mediated increase in CaN activity has been shown to play a role in altered 
synaptic plasticity, neuronal apoptosis, loss of dendritic spines, simplification of 
dendritic arborization and neuritic dystrophies, elevation in glutamate, excitotoxic 
cell death and behavioral impairments observed in some AD mouse models 
(Reese et al., 2008, Wu et al., 2010, Agostinho et al., 2008, Abdul et al., 2009, 
Loo et al., 1993). Pharmacologic inhibition of CaN activity, using FK506, has 
been shown to partially attenuate these effects.  
     CaN is a heterodimer consisting of a 58-64 kDa catalytic subunit (CaNA) 
tightly bound to a 19 kDa regulatory subunit (CaNB) (Rusnak and P. Mertz 2000). 
CaNA is composed of a catalytic domain and a regulatory domain that contains a 
CaNB binding sequence, a CaM binding domain and an autoinhibitory domain. 
The phosphatase is activated when Ca2+/CaM binds to it, triggering the release 
of the autoinhibitory domain from catalytic active site (Klee et al., 1979). CaNA 
can also be activated by proteolytic cleavage of the autoinhibitory domain, 
resulting in a Ca2+/CaM-independent active phosphatase (Klee et al., 1998, 
Perrino et al., 1995, Wu et al., 2004, Mohmmad Abdul et al., 2011). Three 
mammalian isoforms of CaNA (α, β, γ) have been identified, and their amino acid 
sequences have been highly conserved between different organisms (Shibasaki 
et al., 2002). CaNAα and CaNAβ are ubiquitously distributed, while CaNAγ is 
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specifically expressed in the testis. The regulatory subunit CaNB, has two 
mammalian isoforms CaNB1 and CaNB2, which are also highly conserved and 
have four Ca2+ binding “EF- hands” each. CaNB1 is ubiquitously expressed as a 
heterodimer with CaNAα or β, while CaNB2 binds to CaNAγ and is expressed 
only in testis (Rusnak and P. Mertz 2000). 
     CaN is widely expressed in mammalian tissues, but its concentration in brain 
is 10-20 times higher than that found in other tissues (Rusnak and P. Mertz 
2000). In the brain, CaN accounts more than 1% of the total protein content (Klee 
et al., 1988, Yakel 1997). Interestingly, levels of CaNAβ have been reported to be 
significantly upregulated in the Alzheimer’s disease hippocampus (Hata et al., 
2001, Taguchi et al., 2005). CaNAβ has also been shown to modulate tau 
phosphorylation state suggesting its role in development of neurofibrillary tangles 
(Wei et al., 2002). In our study we investigate if upregulation of CaNAβ levels 
regulates APP metabolism in HEK293 cells. With CaNAβ overexpression in 
HEK293 cells we specifically checked if levels of APP and its APP proteolytic 
products including Aβ are being altered. 
Results: 
CaNAβ  overexpression increases levels of FL-APP, APP-CTF & sAPP-Total 
and Aβ40. 
To test whether CaNAβ alters APP metabolism, CaNAβ was overexpressed in 
HEK293 cells (Figure 1A). The effect on levels of endogenous, full-length APP770 
and APP751 (FL-APP) and their proteolytic fragments were assessed. Upon 
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CaNAβ overexpression, we observed a significant increase in levels of 
endogenous FL-APP levels (Figure 3-1(A & B) and APP-CTF’s (CTF-83 and 
CTF-99) (Figure 3-1(C & D). Both CTF-83 and CTF-99 were significantly 
increased when they were quantified individually and normalized to β-actin (data 
not shown). To determine if this increase observed in levels of APP-CTF’s was 
due to increase in FL-APP levels, we normalized APP-CTF levels to FL-APP 
levels and observed no significant change, suggesting that the increase we 
observe in APP-CTF’s levels is solely due to the increase in FL-APP levels 
(Figure 3-1E). 
     Next, we wanted to determine if CaNAβ overexpression in HEK293 could alter 
levels of other APP proteolytic products. Therefore, CaNAβ was co-
overexpressed with Swedish APP695 (APPSwe) in HEK293 cells. Similar to what 
we observed with endogenous FL-APP, CaNAβ co-overexpression resulted in a 
significant increase in FL-APPSwe levels (Figure 3-2 (A & B) and in APPSwe-CTF 
levels (CTF-83 and CTF-99) (Figure 3-2(C & D). Increase in both CTF-83 and 
CTF-99 was observed when normalized to β-actin (data not shown).  Again the 
increase observed in APPSwe-CTF’s levels was due to the increase in FL-APPSwe 
levels (Figure 3-2E). Given that CaNAβ overexpression lead to an increase in FL-
APPSwe and APPSwe-CTF levels, next we used the conditioned media collected 
from these cells to probe for soluble APP levels (s-APPSwe Total). We observed a 
significant increase in levels of sAPPSwe  total with CaNAβ co-overexpression with 
Swedish APP695 (Figure 3-2 (F & G). Lastly we measured levels of Aβ40 in the 
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conditioned media and observed a significant increase in levels of Aβ40 with 
CaNAβ overexpression (Figure 3-2H). This increase in Aβ40 levels was again 
dependent on the increase in levels of FL-APPSwe  (Figure 3-2I). 
CaNAβ overexpression increases Phospho- APPSwe and Phospho- APPSwe -
CTF levels. 
Given CaNAβ’s role as a phosphatase we investigated the effect of 
CaNAβ overexpression on APP phosphorylation. Co-overexpressing CaNAβ and 
APPSwe lead to a significant increase in phospho-Thr668 FL-APPSwe levels 
(Figure 3-3 (A & B). A significant increase in phospho-Thr668 APPSwe-CTF levels 
was also observed upon co-overexpression (Figure 3-3 (D & E). In order 
determine the proportion of FL-APPSwe that was phosphorylated on CaNAβ co-
overexpression, we normalized levels of phospho-Thr668 FL-APPSwe to total FL-
APPSwe and observed no significant change (Figure 3-3C). However, when 
phospho-Thr668 APPSwe-CTF’s were normalized to total APPSwe-CTFs, a 
significant increase in the proportion of phospho-Thr668 APPSwe-CTFs was 
observed (Figure 3-3F). 
CaNAβ overexpression does not alter APP mRNA levels. 
Since we observe an increase in levels of endogeneous and exogeneous FL-
APP upon CaNAβ overexpression it is unlikely that CaNAβ is altering APP 
expression via a transcriptional mechanisms. It is possible that mRNA stability 
could be affected. To assess both of these possibilities we utilized RT-QPCR to 
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determine if CaNAβ overexpression resulted in altered APP mRNA levels. As 
expected, overexpression of CaNAβ in HEK293 cells had no significant effect on 
endogeneous APP mRNA levels suggesting that CaNAβ alters APP levels post-
transcriptionally (Figure 3-4). 
Discussion: 
In our study, we demonstrate that CaNAβ overexpression can regulate APP 
metabolism. We have undertaken a systematic search for regulators of APP 
metabolism utilizing an APP-Gal4/Gal4-UAS luciferase reporter system (Zhang et 
al., 2007, Zuchner et al., 2008). Using this approach we identified CaNAβ as a 
positional candidate gene that could function in regulating APP metabolism. 
Specifically, we observed that CaNAβ knockdown in SH-SY5Y APP Gal4 cells 
that stably carry this reporter system, leads to a significant decrease in AICD-
Gal4 mediated luciferase activity when compared to the non-silencing shRNA 
control. CaNAβ, when overexpressed in the same cell line, led to a significant 
increase in AICD-Gal4 mediated luciferase activity compared to the appropriate 
empty vector (Utreja et al, submitted). Knockdown and overexpression of the 
CaNAβ subunit results in consistent and opposite effects on APP proteolysis as 
measured by this assay, suggesting that CaNAβ plays a reproducible role in APP 
metabolism regulation in this cellular model. Here, we have extended these initial 
studies by investigating whether CaNAβ expression alters other aspects of APP 
proteolysis.  
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     Overexpression of CaNAβ in HEK293 cells lead to a significant increase in 
levels of FL-APP, and APP-CTF’s (CTF-83 and CTF-99), sAPP total and Aβ40 
levels. This increase in FL-APP and APP-CTF’s was observed with endogenous 
levels of APP and overexpressed APPSwe. The increase in APP levels observed 
are most likely due to post-transcriptional effects as no change in APP mRNA 
levels was observed upon CaNAβ overexpression. Given CaN’s role as a 
serine/threonine specific phosphatase, we also examined affect of CaNAβ 
expression on APP phosphorylation state. FL-APP and APP-CTF, which 
increased upon CaNAβ overexpression, were found to be phosphorylated at 
Thr668 residue. When phospho-Thr668 FL-APP and phospho-Thr668 APP-
CTF’s levels were normalized to total FL-APP and APP-CTF levels, respectively, 
and observed no increase in overall phosphorylation of FL-APP but a significant 
increase in phospho-Thr668 APP-CTF’s. Taken together, we conclude that 
increased expression of CaNAβ can alter APP metabolism and lead to increased 
production of Aβ, one of the main causes of Alzheimer’s disease. Therefore, 
downregulating levels of CaNAβ could be used as a potential therapeutic for 
decreasing Aβ levels. 
     CaN is an interesting and an important target in AD because of its critical role 
in learning and memory (Rusnak and P. Mertz 2000). CaN being a 
serine/threonine specific phosphatase mediates the dephosphorylation of several 
cellular proteins and is involved in different signaling pathways. CaN mediated 
dephosphorylation of phospho-CREB (Bito et al., 1996), phospho-NFAT (Abdul 
et al., 2009), phospho-Tau (Liu et al., 2005), phospho-BAD (Wang et al., 1999, 
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Asai et al., 1999, Dineley et al., 2007) and phospho-Gsk3β  (Kim et al., 2009) 
could putatively explain its individual role in synaptic protein loss, 
neuroinflammation (neuronal and astrocytic), decreased neurotransmission, 
hyperphosphorylated tau, and cell death observed in AD models. However, the 
role of CaN in the brain may be very complicated. Overexpression of CaN in 
mice results in altered synaptic function and deficits in memory retention (Kayyali 
et al., 1997). Knockdown of CaN activity facilitates PKA-dependent long-term 
potentiation and increased learning and memory (Malleret et al., 2001). Yet, 
completely knocking out calcineurin in Purkinje cells or in the anterior cortex 
impairs postsynaptic long-term potentiation and worsens cognition (Zeng et al., 
2001). In aged rats, upregulation of CaN activity negatively correlates with 
cognitive performance (Foster et al., 2001). Conversely, downregulation of CaN 
activity using autoinhibitory peptide has shown to improve memory in rodents 
(Malleret et al., 2001). Transgenic Tg2576 mice (AD mouse model), which 
accumulate Aβ and develop cognitive impairments prior to plaque deposition, 
have high CaN activity in central nervous system (CNS). Treatment of these mice 
with CaN inhibitor FK506 improves memory function, indicating that CaN is part 
of the Aβ mediated memory loss pathway (Dineley et al., 2007). It has been 
shown that exogenous application of synthetic amyloid-β or oligomeric 
aggregates to cultured cells leads to a rapid and sustained rise in Ca2+ levels 
along with increase in CaN activity (Reese et al., 2008). Furthermore, in vitro 
evidence indicates that Aβ induces neuronal apoptosis through a CaN-dependent 
mechanism (Agostinho and C. R. Oliveira 2003). Taken together, these studies 
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suggest that CaN is the major phosphatase involved in cognitive and 
neurodegenerative effects of Aβ. However, the ability of CaN to alter Aβ levels 
has not been investigated thoroughly.  
     Previously, cDNA microarray analysis has shown that CaNAβ is the most up-
regulated gene in brain lesions of the early stage of AD (Hata et al., 2001). RT-
PCR analysis from the same study also confirmed that CaNAβ was generally 
upregulated in the hippocampus of the early stage of AD (Hata et al., 2001). The 
exact mechanism for upregulation of CaNAβ in the AD brain remains unknown. 
In our study we report that overexpression of CaNAβ increases levels of FL-APP 
and its proteolytic products including Aβ. Hence, the increased levels of CaNAβ 
observed in AD brains could account for the increased Aβ levels and Aβ 
mediated neurodegenerative affects. Our results indicate that this increase in 
APP levels observed with CaNAβ overexpression is post-transcriptional. Possibly, 
CaNAβ could alter APP protein synthesis or protein degradation affecting the 
levels of APP and APP proteolytic products.  Also, increased APP-CTF’s Thr668 
phosphorylation was observed upon CaNAβ overexpression. CaN being a 
phosphatase, it’s intriguing to observe an increase in APP-CTF phosphorylation 
on CaNAβ overexpression. This could suggest that either CaNAβ overexpression 
does not account for or lead to a change in the overall phosphatase activity of 
CaN, or CaNAβ has an indirect affect on APP-CTF phosphorylation. There has 
been evidence suggesting that overexpression of CaN dephosphorylates GSK-
3β at Ser-9, increasing its activity leading to an increase in phosphorylation of 
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Tau (Kim et al., 2009). Therefore its possible that CaNAβ could affect GSK-3β 
phosphorylation/activity leading to increase in levels of APP-CTF phosphorylation 
at Thr668.  Lastly, activity and levels of CaN in AD brains/AD models have been 
differentially regulated. Specifically, CaN activity is globally reduced in AD brains 
and during aging (Ladner et al., 1996, Karch et al., 2013). Conversely, protein 
levels of CaN are inversely correlated with dementia severity (Karch et al., 2013). 
Therefore it will be important to determine if increased levels of CaNAβ leads to 
altered CaN activity.  
     To our knowledge our study is the first to show that CaNAβ overexpression 
regulates APP levels and proteolysis leading to increased Aβ levels. Results 
presented in our study provide an important link between clinically observed 
increase in CaNAβ levels in AD brains and the observed increase in Aβ levels. 
The results suggest the presence of potentially pathogenic feed forward loop 
between CaN and Aβ.  
Experimental Procedures: 
Plasmids:  
CaNAβ (PPP3CB) overexpression plasmid (pCMV-SPORT6) was purchased 
from Open Biosystems. Swedish APP695 plasmid (pCMV-SPORT5) was a 
generated in our lab by mutating APP695	  (pCMV-SPORT5). 
Antibodies: 
Primary antibodies utilized were: a polyclonal antibody raised to the C-terminus 
of APP (A8717; Sigma Aldrich, Inc), C1/6.1 monoclonal antibody recognizing the 
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C-terminus of APP was kindly provided by P. M. Mathews, an Anti-APP 
monoclonal antibody was used to detect sAPP total levels (22C11, Millipore), a 
monoclonal anti-β-Actin antibody (A5441, Sigma Aldrich, Inc), a polyclonal 
antibody that recognizes APP phosphorylated at Thr668 (D90B8; Cell Signaling 
Technologies), a monoclonal antibody to the CaN catalytic subunit (C1956; 
Sigma, Inc). Secondary antibodies used were: goat anti-Rabbit IR-Dye800 CW 
(926-3211;LiCor Inc.) and/or goat anti-Mouse IR Dye 680 (926-3200; LiCor Inc.). 
Cell culture and Overexpression experiments: 
HEK-293 cells were purchased from the American Type Culture Collection 
(ATCC) (Manassas, VA). HEK-293 cells were cultured in Dulbecco’s modified 
Eagles medium (DMEM), supplemented with 10% fetal bovine serum, penicillin 
(25,000 U/ml) and streptomycin (25,000 µg/ml). HEK293 cells were then 
transiently transfected with CaNAβ overexpression construct and an appropriate 
empty vector control.  48 hours post-transfection, cell lysates were collected and 
used for Western Blot analysis. Conditioned media from the above experiments 
was used to detect s-APP and Aβ levels. 
Western Blot Analysis:  
After the treatments, cells were washed twice with cold PBS and then lysed in 
RIPA Buffer (50 mM Tris, 150 mM NaCl, 1% SDS, 1% NP-40, 0.5% deoxycholate, 
pH 8.0 containing HALT protease and phosphatase inhibitor cocktail 
(ThermoFisher). 10µl of lysates were used for protein assay with the help of BCA 
Protein Assay Kit (Pierce, Inc.). The BCA protein utilizes a standard curve 
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generated by RIPA standards (different dilutions of BSA protein in RIPA buffer). 
According to the protein concentrations, samples for Western Blot were prepared 
using the 4x Nupage LDS sample buffer (InVitrogen, Inc.) containing 0.2% BME 
(β-Mercaptoethanol, Sigma Aldrich). Equal volumes of protein were loaded on to 
each well of NuPAGE 4-12% Bis Tris Gel. A molecular weight ladder (Two color 
protein standard, 928-40001, Li-COR) was always run along with the 
experimental samples. From the gel the proteins were transferred on to 0.25 µm 
PVDF membrane (Millipore) using a semi-dry transfer apparatus. Blots were 
probed with different antibodies and the target protein densitometry was 
quantified using the software (ODYSSEY Infra red imaging system, Application 
software) and normalized to the densitometry of β-actin. All Western blot 
experiments were performed in triplicates.  
RNA extraction and Quantitative PCR: 
48 hours post-transfection, cells were washed with cold PBS and total RNA was 
isolated using RNeasy Mini Kit (Qiagen Inc.). To quantify APP mRNA levels, 
cDNA was synthesized using total RNA, N6 random primers and SuperScript II 
Reverse Transcriptase (Invitrogen). cDNA was then diluted 1:15 using RNase 
free water and mixed with APP or GAPDH primer/probe sets (Applied Biosys- 
tems, Inc.; APP Catalog # Hs00169098_m1; GAPDH Cat- alog # 
Hs99999905_m1), 2× PCR Universal Master Mix (Applied Biosystems, Inc.) and 
amplified using an ABI 7500 Real Time PCR system following the manufacturer's 
directions. GAPDH was used as an internal control. To determine differences in 
APP mRNA levels, we utilized the ΔΔCt method and calculated fold change. 
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Aβ ELISA: 
Aβ levels were determined using commercially available Human/Rat βAmyloid 
(40) ELISA Kit Wako (Wako Catalog #294-62501, 96 tests) according to the 
manufacturer’s instructions. Conditioned media obtained from the treatments 
were diluted in sample dilutent available in the kit in (1: 30) ratio. Conditioned 
media was then used for measuring secreted Aβ40. In brief, Aβ40 levels (pg/ml) 
were quantified using sandwich enzyme-linked immunosorbent (ELISA) assay. 
Statistical Analysis: 
Values in the text and figures are presented as means ± standard errors of at 
least three independent experiments. Equal variance or separate variance two-
sample student’s t-test were used, as appropriate, to compare two groups. “*” 
indicates p < 0.05, “**” indicates p < 0.01, and “***” indicates p < 0.001. “n.s.” 
indicates p-values greater than 0.05. 
Conclusions:  
This work demonstrates that CaNAβ acts as an APP metabolism regulator and 
can play a significant functional role in AD pathogenesis. CaNAβ was identified 
as one of the most upregulated mRNA’s in hippocampus of AD brains and a 
candidate positional gene that could function as a putative APP metabolism 
regulator. In our study we specifically demonstrate that: (i) CaNAβ 
overexpression alters APP proteolysis in HEK293 cells and leads to an increased 
levels of FL-APP, APP-CTF’s, s-APP total and, most importantly, increased Aβ40 
levels. Our results suggest that the clinically observed increase in CaNAβ levels 
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in AD brains may directly alter APP proteolysis leading to increased Aβ levels, 
suggesting the presence of potentially pathogenic feed forward loop between 
CaNAβ and APP/ Aβ; (ii) We observed an increased phosphorylation of Thr668 
residue on APP and APP-CTF’s upon CaNAβ overexpression, which suggests 
that CaNAβ might play an indirect role in regulating APP phosphorylation. It will 
be important in the future to dissect how CaNAβ levels may co-relate to CaN 
activity and also investigate the mechanism by which CaNAβ is altering APP 
levels and its phosphorylation simultaneously. Overall, we conclude that 
increased levels of CaNAβ may contribute to cognitive and neurodegenerative 
effects of Aβ, by regulating APP metabolism. Therefore down-regulating levels of 
CaNAβ can be investigated as a potential therapeutic approach for AD. 
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Figure Legends: 
 
Figure 3-1. CaNAβ  overexpression alters levels of endogenous APP and 
APP-CTF’s. 
CaNAβ or an empty vector was transiently transfected into HEK293 cells. (A) 
Representative western blot showing an increase in levels of CaNAβ and 
endogenous FL-APP when CaNAβ is overexpressed. (B) Quantification shows a 
significant increase in levels of endogenous FL-APP. β-Actin was used as a 
loading control. (C) A representative Western blot showing an increase in levels 
of endogenous APP-CTF’s upon CaNAβ overexpression. (D) Quantification of 
the above data showed that the increase in APP-CTF’s is significant. (E) APP-
CTF’s levels were normalized to FL-APP levels and no significant difference in 
the ratio was observed. Values are means ± standard errors of 3 independent 
experiments. . “*”: p < 0.05 and “n.s.” : p-values > 0.05 (Student’s t-test). 
Figure 3-2.  CaNAβ co-overexpression with APPSwe alters levels of APP and 
APP proteolytic products. 
CaNAβ and APPSwe were co-overexpressed in HEK293 cells. An empty vector 
was also co-overexpressed with APPSwe plasmid as the control for the 
experiment. (A) A representative Western blot showing an increase in FL-APPSwe 
upon CaNAβ overexpression.  (B) Quantification of FL-APP levels demonstrate a 
significant increase in FL-APPSwe levels was observed. β-Actin was used as the 
loading control. (C) An increase in levels of APPSwe-CTF’s was also observed 
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with CaNAβ overexpression. (D) Quantification of the above data showed that 
the increase in APPSwe-CTF’s is significant. (E) APPSwe-CTF levels were 
normalized to FL-APPSwe levels and no significant difference was observed. (F) 
Conditioned media from co-transfected cells was used to assess sAPP total 
levels. (G) Quantification of the sAPP total Western blot data shows a significant 
increase in sAPP Total levels was observed with CaNAβ overexpression. (H) 
CaNAβ overexpression led to a significant increase in levels of Aβ40 as assessed 
by ELISA assay. (I) Aβ40 levels were normalized to levels of FL-APP and no 
significant difference was observed. Values are means ± standard errors of 3 
independent experiments. “*”: p < 0.05, “**”: p < 0.01, “***” :p < 0.001 and “n.s.” : 
p-values > 0.05 (Student’s t-test). 
Figure 3-3. CaNAβ  co-overexpression with APPSwe leads to increase in 
Thr668 phosphorylation. 
(A) Representative western blot from the HEK293 cell lysates co-overexpressing 
CaNAβ and APPSwe. (B) Quantification of the above experiment shows an 
increase in levels of phospho-Thr668 FL-APPSwe. (C) When phospho-Thr668 FL- 
APPSwe levels were normalized to total FL-APPSwe levels, no significant difference 
was observed showing that this increase was proportional to the levels of FL-
APPSwe. (D) Western blot showing an increase in phospho-Thr668 APPSwe -
CTF’s on CaNAβ overexpression. (E) Quantification of the above experiment 
revealed that the increase was significant. (F) Normalization of phospho-Thr668 
APPSwe-CTF levels to total APPSwe-CTF’s showed a significant increase in the 
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proportion APPSwe-CTF that were phosphorylated at Thr668. Values are means ± 
standard errors of 3 independent experiments. “*”: p < 0.05, “**”: p < 0.01 and 
“n.s.” : p-values > 0.05 (Student’s t-test). 
Figure 3-4. CaNAβ  overexpression does not alter APP mRNA levels. 
No differences in Fold change of endogenous APP mRNA were observed upon 
CaNAβ overexpression in HEK 293 cells, suggesting that 
CaNAβ overexpression does not regulate APP transcription.  
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FIGURES: 
 
         
              
Figure 3-1A. CaNAβ  overexpression increases levels of endogenous APP. 
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Figure 3-1B. CaNAβ  overexpression increases levels of endogenous APP.  
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Figure 3-1C. CaNAβ  overexpression increases levels of endogenous APP-
CTF’s. 
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Figure 3-1D. CaNAβ  overexpression increases levels of endogenous APP-
CTF’s. 
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Figure 3-1E. CaNAβ  overexpression increases levels of APP-CTF’s, but the 
increase is dependent on the increase in endogenous APP. 
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Figure 3-2A.  CaNAβ co-overexpression with APPSwe increases levels of FL-
APP.  
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Figure 3-2B. CaNAβ co-overexpression with APPSwe increases levels of FL-
APP.  
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Figure 3-2C.  CaNAβ co-overexpression with APPSwe increases levels of 
APP-CTF’s. 
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Figure 3-2D. CaNAβ co-overexpression with APPSwe increases levels of 
APP-CTF’s.  
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Figure 3-2E. CaNAβ co-overexpression with APPSwe leads to an increases 
APPSwe-CTF’s but the increase is dependent on the increase in FL- APPSwe.  
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Figure 3-2F.  CaNAβ co-overexpression with APPSwe increases levels of  
sAPP. 
 
 
 
 
 
 
 
 
 
	   129	  
 
 
 
 
 
Figure 3-2G.  CaNAβ co-overexpression with APPSwe increases levels of 
sAPP. 
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Figure 3-2H.  CaNAβ co-overexpression with APPSwe increases levels of Aβ .  
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Figure 3-2I.  CaNAβ co-overexpression with APPSwe increases levels of 
Aβ  which is dependent on FL-APP levels.  
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Figure 3-3A.  Co-overexpressing CaNAβ  and APPSwe lead to a significant 
increase in phospho-Thr668 FL-APPSwe levels  
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Figure 3-3B.  Co-overexpressing CaNAβ  and APPSwe lead to a significant 
increase in phospho-Thr668 FL-APPSwe levels  
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Figure 3-3C.  Co-overexpressing CaNAβ  and APPSwe lead to a significant 
increase in phospho-Thr668 FL-APPSwe levels which was dependent on 
Total FL- APPSwe levels. 
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Figure 3-3D.  Co-overexpressing CaNAβ  and APPSwe lead to a significant 
increase in phospho-Thr668 APPSwe-CTF’s levels.  
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Figure 3-3E.  Co-overexpressing CaNAβ  and APPSwe lead to a significant 
increase in phospho-Thr668 APPSwe-CTF’s levels.  
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Figure 3-3F.  Co-overexpressing CaNAβ  and APPSwe lead to a significant 
increase in phospho-Thr668 APPSwe-CTF levels which was dependent on 
Total APPSwe-CTF levels. 
 
 
 
 
 
	   138	  
 
 
 
 
 
Figure 3-4. CaNAβ  overexpression does not alter APP mRNA levels. 
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CHAPTER 4 
Pharmacological Inhibition of Calcineurin using Cyclosporin A (CsA) in 
Drosophila AD models 
Introduction: 
In addition to FK506, calcineurin (CaN) phosphatase activity can also be inhibited 
by cyclosporin A (CsA) (Liu et al., 1991). CsA is an immunosuppressant drug 
widely used to prevent organ transplant rejection (Mahmud et al., 2010). 
CsA interferes with the growth and activity of T-cells leading to a 
compromised immune system. In order to become functional, CsA binds to the 
ubiquitously expressed intracellular protiens called cyclophilins (CyP) (Hsu and I. 
M. Armitage 1992, Pflugl et al., 1993). The CsA-CyP complex binds to CaN and 
noncompetitively inhibits its serine-threonine phosphatase activity. The molecular 
model for the interaction between CsA-CyP complex and CaN has already been 
proposed (Clipstone and G. R. Crabtree 1992, Foor et al., 1992, Ho et al., 1996). 
Inhibition of CaN by CsA prevents the nuclear translocation of NFAT, leading to 
inhibited transcription of many T-cell cytokines and related genes. 
     Most of the isoforms of both CaN and CyP are widely distributed among 
different tissues. The CyPs have the peptidyl proline cis-trans isomerase activity. 
CyPs have been identified in form of two different classes, the CyPA family, 
found in both the cytoplasm and nucleus interms of the distribution, and the 
CyPB family, which are found in the endoplasmic reticulum and secretory 
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pathways. CyPB family of CyPs possess a signal sequence directing them into 
the endoplasmic reticulum and secretory pathways (Swanson et al., 1992). CsA 
is a potent inhibitor of both the families of CyPs (CyPA & CyPB) peptidyl proline 
cis-trans isomerase activity and this accounts for its ability to block the immune 
response completely. Atleast, fifteen different proteins exsist within the CyP 
family of immunophilins. All of them are able to bind to CsA, but only few CsA-
Cyp complexes out of them can potently inhibit CaN activity (Swanson et al., 
1992). As discussed above, both CyPA and CyPB complex along with CsA can 
inhibit CaN activity. Both CsA and FK506 treatment affect the same Ca2+ 
dependent signal transduction pathways and inhibit the intracellular Ca2+ target 
CaN (Liu et al., 1991).  
      Ca2+ dyshomeostasis has been shown to be critically involved in 
pathogenesis of Alzheimer’s disease, where levels and activity of this Ca2+ 
dependent phosphatase CaN are misregulated (Demuro et al., 2010). Misfolded 
amyloid beta peptide (Aβ), a pathological hallmark of AD has been shown to 
activate CaN and its downstream signaling pathways. Upregulation of CaN 
activity in aged rats negatively correlates with their cognitive performance (Foster 
et al., 2001). Conversely, using an autoinhibitory peptide for inhibition of CaN 
activity has been shown to improve memory deficits in the rodents (Malleret et al., 
2001). The Tg2576 mouse AD model, which accumulates Aβ and develop 
cognitive impairments, has high CaN activity in the central nervous system (CNS). 
FK506 mediated inhibition of CaN activity improves memory function in these 
rodents, indicating that CaN is part of the Aβ mediated memory loss pathway 
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(Dineley et al., 2007). Exogenous application of synthetic Aβ or oligomeric 
aggregates to cultured cells leads to a rapid and sustained rise in Ca2+ levels 
along with increased CaN activity (Reese et al., 2008). Furthermore, some in 
vitro studies have shown that Aβ induces neuronal apoptosis through a CaN-
dependent mechanism (Agostinho and C. R. Oliveira 2003). Taken together, 
these studies suggest that CaN is the major phosphatase involved in cognitive 
and neurodegenerative effects of Aβ. However, the ability of CaN to alter Aβ 
levels has not been investigated thoroughly. In the present study, we investigated 
how pharmacological inhibition of CaN using CsA alters APP metabolism and 
level of Aβ in vivo.  
 
Results: 
CaN inhibition using CsA decreases AICD mediated gene transcription in 
vivo. 
We undertook a systematic search for regulators of APP metabolism utilizing an 
APP-Gal4/Gal4-UAS luciferase reporter system (Zhang et al., 2007). In this 
system, production of AICD-Gal4 via normal α-, β- and γ-secretase processing 
leads to transcriptional activation of luciferase activity. We identified CaNAβ as a 
potential regulator of APP metabolism. Overexpression of CaNAβ lead to an 
increase in AICD mediated luciferase activity and knockdown of CaNAβ lead to a 
decrease in AICD mediated luciferase activity. We also discovered that 
pharmacological inhibition of CaN using FK506 lead to decrease similar to the 
decrease in AICD mediated gene transcription in vitro and in in vivo. FK506 
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treatment of γ-secretase reporter flies lead to decrease in AICD mediated GRIM 
transcription rescuing the rough eye phenotype of these flies. 
       To confirm that this pharmacologic effect was due to inhibition of CaN, we 
inhibited CaN activity with CsA in a Drosophila melanogaster γ-secretase activity 
reporter line (Guo et al., 2003). This reporter relies on flies that carry human 
APP-CTF fused to Gal4 (APP-CTF99-Gal4) with expression restricted to the fly 
eye. Exogenously expressed APP-CTF-Gal4 can be cleaved by endogenous 
γ-secretase activity resulting in generation of AICD-Gal4, which translocates to 
the nucleus and transactivate the Gal4/UAS controlled GRIM reporter gene. 
GRIM induces apoptosis, and in this case since its expression is restricted to the 
photoreceptor cells, the morphology of the external eye is disrupted (causing a 
so called “rough eye phenotype”).  
         γ-secretase reporter flies were raised on food containing CsA or vehicle. 
The eye phenotypes of progeny were scored based on roughness (+ to +++; 
(Figure 4-1 (A-D)). Treatment of the reporter flies with CsA resulted in 
suppression of the rough eye phenotype, indicating an in vivo decrease in AICD 
mediated GRIM activity, and suggesting a decrease in levels of AICD produced 
(Figure 4-1 (E)). 
In vivo CaN inhibition using CsA alters levels of APP proteolytic products 
leading to a decrease in Aβ  levels.  
Next, we used a more relevant in vivo disease model, which recapitulates 
amyloidogenic processing of APP and leads to production of Aβ. This Drosophila 
	   143	  
AD model stably overexpresses human APP and human BACE in the central 
nervous system (AD flies).  Consistent with our observations with FK506 
treatment of these AD flies, CsA treatment also resulted in an increase in brain 
levels of APP-CTF but after quantification the increase was not significant (Figure 
4-3 (A & B). While we also observed a small increase in levels of FL-APP in 
these fly brains, these effects were not significant (Figure 4-2 (A & B)). 
Qualitatively the data suggested that APP and APP-CTF’s are being altered but 
quantitative analysis of the same did not show the increase was significant.  
       Next we wanted to check if CsA treatment lowers brain Aβ load in this 
Drosophila AD model like FK506 treatment. We observed a decrease in levels of 
Aβ40 and Aβ42 in the brains of AD flies treated with CsA at a lower concentration 
but we did not observe a decrease in flies treated with CsA 100nM (Table 4-1). 
This decrease in Aβ load observed with at least one concentration of CsA led us 
to investigate the other Aβ related pathologies observed in this AD model 
(Chakraborty et al., 2011). 
In vivo CaN inhibition using CsA rescues motor reflex deficit and other 
morphological deficits.  
Previous characterization of this Drosophila AD model has revealed brain 
pathology that is similar to human AD patients, including accumulation of Aβ 
containing puncta, decreased dendritic and axonal fields in areas of the brain 
used for learning and memory, decreased motor reflexes, and importantly the 
lack of immediate recall memory (Chakraborty et al., 2011).    
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       Therefore, we tested the ability of CsA treatment to rescue CNS function. 
Initially, CNS function was tested by assessing broad motor reflex function. The 
negative geotaxis climbing assay assesses the reflexive climbing behavior of flies 
in response to a mechanical stimulus (Iijima et al., 2004, Le Bourg and F. A. Lints 
1992). By assaying the fly’s ability to climb to the top of a vial in a set time period 
we were able to assess broad nervous system function of reflex behavior of 
these AD model flies treated with CsA. AD flies treated with CsA showed 
significantly improved climbing ability (Figure 4-4 (A)) when compared to vehicle 
control (DMSO) treated flies. We also checked if CsA treatment of AD flies leads 
to any improvement in the external morphological deficits, which were initially 
observed in the AD flies. Pharmacological inhibition of CaN using CsA (10 & 100 
nM) lead to significant improvement in the presence of crumpled wings and 
external melanotic masses in these AD flies (Figure 4-4 (B)). These results 
suggest that CaN inhibition using CsA can rescue central nervous system 
function. Rescue in these functions might not be completely dependent on Aβ. 
Discussion: 
The results presented in our study suggest that CaN can act as a regulator of in 
vivo APP processing. We observed that pharmacological inhibition of CaN using 
CsA decreases AICD mediated reporter gene expression in γ-secretase reporter 
flies. Given this observed decrease in AICD levels, we hypothesized that CaN 
inhibition might alter APP processing in the Drosophila human APP & human 
BACE AD model. Therefore, using this Drosophila AD model expressing human 
APP and human BACE throughout the central nervous system, we inhibited CaN 
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using CsA and observed altered APP processing. An increase in FL-APP and 
APP-CTF’s was observed by qualitative analysis of the data but these results 
were not significant. Decrease in Aβ levels was observed in AD fly brains but 
only at the lower concentration of CsA (10 nM) used. In addition, we also 
observed a CsA mediated rescue effect on the morphological and motor reflex 
deficits observed in this AD model.  
          The inconsistency in APP metabolism results obtained with CsA mediated 
inhibition of CaN, is somewhat puzzling but can be possibly due its off-target 
effects or involvement of CsA in other signaling pathways apart from its role as 
CaN inhibitor. CsA is a potent immunosuppressor and holds the ability to block 
the NFAT mediated transcription gene transcription affecting the levels of 
cytokine genes in activated T cells (Rovira et al., 2000). Apart from its ability to 
block the CaN/NFAT signaling pathway, recent studies suggest that CsA also 
blocks the activation of the protein kinase JNK (c-jun NH2-terminal kinase)  
(stress activated protein kinase) and the mitogen-activated protein kinase p38-
signaling pathway. As discussed above CsA has a beneficial role in organ 
transplantation, but conversely is also responsible for the side effects like 
hypertension, renal and muscle toxicity (Matsuda and S. Koyasu 2000). Its has 
been suggested that these effects of CsA are probably dependent on ROS 
generation (Buetler et al., 2000). 
         Additionally, CsA is also known to block the mitochondrial permeability 
transition pore (PTP) opening. This blockage has been accounted for its high 
affinity to cyclophilin D. Blocking of this mitochondrial PTP is independent of CsA 
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ability to inhibit CaN and its immunosuppressive effects(Zamzami et al., 1996, 
Hortelano et al., 1997, Matsumoto et al., 1999, Vergun et al., 1999). PTP opening 
blockage has been proposed to be the mechanism underlying the protective 
action of CsA against ischemic and ischemic/reperfusion injuries. CsA is also 
known for its use in treating Traumatic Brain Injury (TBI). TBI impairs long-term 
potentiation of synaptic transmission. Post-TBI administration of CsA results in 
amelioration of the impaired LTP. TBI results in alterations in hippocampal 
synaptic plasticity leading to deficits in learning and memory. Administration of 
CsA, which is known to improve mitochondrial function, has been suggested to 
prove an effective treatment of TBI. Therefore, CsA plays many other roles apart 
from just acting as a CaN inhibitor. 
        Apart from the off target affects of CsA, the discrepancy in results could also 
be explained by differential role for CaN signaling in distinct cell types at different 
time points in these tasks. Since neurons act as one of the best cellular models 
to detect changes in Ca2+ activated CaN activity, it would be interesting to 
determine if CsA mediated inhibition of CaN in neurons alters APP processing 
and decreases Aβ levels more specifically.  
        Lastly, since we observed a rescue affect on morphological defects and 
deficits of central nervous system in terms of motor reflex deficit, analyzing the 
memory and neuroanatomical deficits would be necessary to see if CsA can 
completely rescue all Drosophila AD model defects.  Also results from this study 
were similar but not completely identical to results obtained from our FK506 
study, which could be explained by the off-target affects of CsA. Overall we 
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conclude further investigation is needed to determine if CsA can completely 
rescue Aβ mediated neurodegenerative affects. 
Experimental Procedures: 
Antibodies: 
Primary antibodies utilized were: a polyclonal antibody raised to the C-terminus 
of APP (A8717; Sigma Aldrich, Inc), a monoclonal anti-β-Actin antibody (A5441, 
Sigma Aldrich, Inc). Western blot secondary antibodies used were goat anti-
Rabbit IR-Dye800 CW (LiCor Inc.) and/or goat anti-Mouse IR Dye 680 (LiCor 
Inc.).  
Pharmacologic Inhibition of CaN: 
For inhibition of CaN, CsA (Sigma-Aldrich) was dissolved in DMSO (99.9%) to 
obtain a final concentration of 10 mM. This stock was further diluted in complete 
media to obtain final CsA concentrations of 100 nM or 3 µM. The final DMSO 
concentration was 0.1%, therefore 0.1% DMSO was used for the vehicle control. 
To treat flies with CsA, the drug was dissolved in DMSO (99.9%) to a final 
concentration of 0.1 mM and was further dissolved in Drosophila food to obtain 
final concentrations of 10 nM and 100 nM.  
Western Blot Analysis:  
Fly heads were collected six days after eclosion from respective genotypes 
and/or treatments and lysed in RIPA buffer (3 µL per head; 50 mM Tris, 150 mM 
NaCl, 1% SDS, 1% NP-40, 0.5% deoxycholate, pH 8.0 and protease and 
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phosphatase inhibitor cocktail (ThermoFisher)). Samples for Western blot were 
prepared using the 4x NuPage LDS sample buffer (Invitrogen) containing 0.2% 
β-Mercaptoethanol (Sigma Aldrich). A volume equal to 15-20 fly heads or 30-50 
µg of the protein from cell lysates was loaded into each well of NuPAGE 4-12% 
Bis Tris gel (Invitrogen). A molecular weight ladder (Two color protein standard, 
928-40001, Li-COR) was always run along with the experimental samples. 
Densitometry of individual bands were quantified using the software (ODYSSEY 
Infra red imaging system, Application software) and normalized to the 
densitometry of β-actin. All Western blot experiments were performed in 
triplicates. 
Aβ ELISA: 
In AD flies, Aβ40 and Aβ42 levels were determined using commercially available 
human Aβ specific ELISA kits (BetaMark, Covance, Dedham, MA) according to 
the manufacturer’s instructions. Lysates were obtained by homogenizing heads 
of AD flies raised on food containing CsA or 0.1% DMSO. For each treatment 
tested, homogenates from 100 fly heads were used for each drug concentration. 
These heads were mechanically homogenized and then centrifuged for 20 min at 
14,000 rpm. After centrifugation the supernatant was collected and stored in -80° 
C until needed.  
Drosophila Stocks and Genetics: 
All crosses and stocks were maintained at 25° C. Normal food and fly food 
containing pharmacological agents was prepared as described previously 
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(Chakraborty et al., 2011). For experiments utilizing the APP-Gal4; UAS-GRIM 
system, the effects on adult fly eye morphology were recorded by photographing 
the eyes (SPOT digital camera mounted to a Leica Mz 125 stereomicroscope). 
Using these images, eye phenotype was scored (+ to +++) for effects on eye 
morphology. “+” is a rough eye, where at least one-half of the eye field is wild 
type. “++” is a rough eye where more than one-half of the eye is rough, usually 
affecting the whole eye, but not always. “+++” is a strong rough eye where the 
entire eye is affected, and there is a strong loss of pigment in the posterior one-
half of the eye. To study the effect of the pharmacological drug CsA on GMR-
APP-Gal4, UAS:GRIM / Cyo  flies, they were outcrossed to  w1118 flies on either 
the drug food (CsA) or the vehicle (0.1% DMSO) and progeny flies were scored 
for the eye morphology 24 hours after eclosion.   
Behavioral testing and training: 
Flies were maintained in a 12:12 light:dark cycle at 25° C and 60% 
humidity.  Flies were collected and the assay was performed as described 
previously (Chakraborty et al., 2011). For climbing assays, 100-150 flies were 
assayed for each treatment. The average climbing index for days 1-11 and days 
12-21 was binned.  
Statistical Analysis: 
Values in the text and figures are presented as means ± standard errors of at 
least three independent experiments. Equal variance or separate variance two-
sample student’s t-test were used, as appropriate, to compare two groups. “*” 
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indicates p < 0.05, “**” indicates p < 0.01, and “***” indicates p < 0.001. “n.s.” 
indicates p-values greater than 0.05. For our in vivo studies, to determine if there 
was a statistically significant change in phenotype relative to wild type we 
performed a G-test of homogeneity and reported the p-values. To analyze 
behavioral-testing data, a one-way ANOVA and Tukey’s post-hoc analysis was 
used to determine significant difference between DMSO control and treatment 
groups.   
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FIGURES: 
 
                                      
 
Figure 4-1. Calcineurin inhibition regulates AICD-Gal4 mediated reporter 
gene expression in vivo. Treatment of GMR-APP-Gal4, UAS:GRIM flies with 
CsA suppresses rough eye phenotype. (A-D) The eye phenotypes of progeny 
were scored based on a roughness scale (+ to +++). (E) Quantitative analysis of 
eye phenotype distribution.  “***”: p < 0.001 (G-test of homogeneity). 
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Figure 4-2. Calcineurin inhibition in AD flies alters APP levels. (A) 
Representative Western blot of fly heads from AD flies treated with either vehicle 
or CsA (10nM & 100nM) and probed with A8717, β-Actin antibodies (B) 
Quantification of the total APP Western blot reveals no significant change in FL-
APP levels. Values are means ± standard errors of 3 independent experiments. 
“n.s.” : p-values > 0.05. (Student’s t-test). 
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Figure 4-3. Calcineurin inhibition in AD flies alters APP-CTF’s levels. (A) 
Representative Western blot of fly heads from AD flies treated with either vehicle 
or CsA (10nM & 100nM) and probed with A8717, β-Actin antibodies (B) 
Quantification of the total APP-CTF’s Western blot reveals no significant change 
in APP-CTF levels. Values are means ± standard errors of 3 independent 
experiments. “n.s.” : p-values > 0.05 (Student’s t-test). 
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Table 4-1. Calcineurin inhibition in AD flies decreases Aβ levels. Aβ levels in 
AD fly brain homogenates were assessed using isoform specific ELISA. CsA 
(10nM) treatment results in decreased Aβ40 and  Aβ42 levels CsA (100nM) shows 
an increase in Aβ40 and  Aβ42 levels instead. ELISA was performed in triplicate 
from a sample consisting of population of flies including several independent 
generations. 
 
 
 
 
 
 
 
Fly Homog (pg/ml)
Sample Aß40 Aß42
1. Fk506 100nM 4.61 ± 1.29 0.30 ± 0.47
2. Fk506 10 nM 13.5 ± 0.3 3.5 ± 0.1
3. DMSO 0.1% 44.0 ± 2.1 5.6 ± 0.8
4. CsA 10 nM 23.0 ± 0.9 2.9 ± 0.3
5. CsA 100nM 158 ± 3.0 39 ± 1.7
GMR/+WT 0.45 ± 0.30 3.13 ± 1.96
GMR-Abeta42 1.97 ± 0.30 107 ± 8.4
Fly Homog (pg/ml)
Sample Aß40 Aß42
1. Fk506 100nM 4.61 ± 1.29 0.30 ± 0.47
2. Fk506 10 nM 13.5 ± 0.3 3.5 ± 0.1
3. DMSO 0.1% 44.0 ± 2.1 5.6 ± 0.8
4. CsA 10 nM 23.0 ± 0.9 2.9 ± 0.3
5. CsA 100nM 158 ± 3.0 39 ± 1.7
GMR/+WT 0.45 ± 0.30 3.13 ± 1.96
GMR-Abeta42 1.97 ± 0.30 107 ± 8.4
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Figure 4-4A. Calcineurin inhibition of AD flies improves behavioral deficits. 
Quantification of climbing behavior between the elav; APP; BACE heterozygous 
flies on vehicle control (DMSO) compared to CsA (10 & 100nM). 
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Figure 4-4B. Calcineurin inhibition of AD flies improves morphological 
deficits. Quantification of percentage of elav; APP; BACE heterozygous flies 
having crumpled wings and melanotic masses on vehicle control (DMSO) 
compared to CsA (10 & 100nM). 
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CHAPTER 5 
Identification of CaNB2 (PPP3R2) as a putative APP metabolism regulator 
Introduction: 
 The presence of candidate genes on Chromosome 9, and 10 that can account 
for some of the genetic risk of developing Alzheimer’s disease were reported by 
different genome-wide linkage analysis and linkage disequillibirum studies. 
(Saunders et al., 2003, Blacker et al., 2003, Bertram et al., 2007). Some of these 
genes could act as risk factors for AD by functionally regulating APP metabolism, 
by altering Aβ production or degradation. Therefore, using an AICD based 
functional screen, all of these positional candidate genes were tested for their 
ability to regulate APP metabolism. The screen made use of the gene 
transactivation properties AICD-Fe65-Tip60 trimeric complex (Zhang et al., 2007). 
APP695 was engineered with a Gal4 DNA binding domain to produce APP-Gal4 
fusion protein. This APP-GAL4 fusion protein along with a GAL4-UAS reporter 
construct bearing the luciferase gene were stably overexpressed in SHSY5Y-
APPGAL4 cells. APP-Gal4 undergoes endogenous proteolysis in these cells to 
produce AICD-Gal4 instead of just AICD. Once released, AICD-Gal4 forms 
trimeric complex with endogenous Fe65 (adaptor protein) and Tip60 (histone 
acetyl transferase) and binds to Gal4 DNA binding domain activating the 
transcription of a firefly luciferase gene under the control of Gal4-UAS (GAL4-
UAS-LUC) (Zhang et al., 2007). Further, RNAi knockdown of ~ 600 positional 
candidate genes was carried out in SHSY5Y-APP-Gal4 cells. The principle 
underlying this screen was, that if any of these genes are involved in regulation 
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of APP metabolism, knockdown of that particular gene will alter APP metabolism, 
leading to a change in amount of AICD being produced and hence AICD-
mediated transcription of luciferase gene (Zhang et al., 2007). 
            We identified thirty genes whose knockdown lead to significant changes 
in luciferase activity. Out of which we picked two such genes present on 
Chromosome 9 and 10 whose knockdown lead to a highly significant changes in 
luciferase activity indicating there role in regulating APP metabolism (Khandelwal, 
Zhang et al, unpublished data). These genes encode the catalytic and the 
regulatory subunit of the serine/threonine protein phosphatase Calcineurin (CaN). 
PPP3CB or CaNAβ (catalytic subunit of Calcineurin) is located on chromosome 
10 and PPP3R2 or CaNB2 (regulatory subunit of Calcineurin) is located on 
chromosome 9 (Klee et al., 1979). We previously described CaNAβ ability to 
regulate APP metabolism in Chapter 2. Therefore, we will focus on role of 
CaNB2 in APP metabolism in this chapter. 
             Specifically, Calcineurin (CaN) is a member of the serine/threonine 
protein phosphatase family and the only known phosphatase activated by Ca2+ 
and Calmodulin (CaM) (Klee et al., 1979). CaN acts as a heterodimer consisting 
of a 58-64 kDa catalytic subunit (CaNA) tightly bound to a 19 kDa regulatory 
subunit (CaNB) (Rusnak and P. Mertz 2000). CaN A has four different domains 
namely, the catalytic domain, the regulatory domain containing a CaNB binding 
sequence, the CaM binding domain and the autoinhibitory domain. CaN 
becomes activated after Ca2+/CaM bind to it and trigger the release of the 
autoinhibitory domain portion of the catalytic domain from the active site (Klee et 
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al., 1979, Perrino and B. A. Martin 2001, Wu et al., 2004, Mohmmad Abdul et al., 
2011). Proteolytic cleavage of the autoinhibitory domain of CaNA, also results in 
a Ca2+/CaM-independent active phosphatase. CaNA (α, β, γ) have been 
identified as three mammalian isoforms of CaNA and their amino acid sequences 
are highly conserved between different organisms (Shibasaki et al., 2002). 
CaNAα and CaNAβ isoforms are ubiquitously distributed, while CaNA-γ isoform 
is specifically expressed in the testis. Two mammalian isoforms of CaNB exsist 
namely, CaNB1 and CaNB2 which have four Ca2+ binding “EF- hands “each and 
are highly conserved (Rusnak and P. Mertz 2000). CaNB1 is ubiquitously 
expressed as a heterodimer with CaNAα or β, while CaNB2 binds to CaNAγ and 
is expressed only in testis. N-terminal myristolylation is found on CaNB subunit, 
which has been suggested to assist the interaction of CaN with lipid membranes 
and also its localization to the plasma membrane. Conversely, some research 
groups have shown that the interaction of CaN with the phospholipid membranes 
is myristoyl independent. These groups suggest that this interaction is dependent 
on the phospholipid-binding site located on the CaNB, which helps in its 
association with cytoskeleton.  
             In our study, we specifically wanted to test the role of CaNB2, which may 
regulate CaNAβ activity or function. It is also possible that CaNB2 has its own 
independent function apart from being a part of the CaN complex. The results 
obtained with overexpression of CaNB2 in HEK293 cells have been described 
below. 
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Results: 
Calcineurin knockdown and overexpression, modulates AICD mediated 
gene transcription in vitro. 
Using the AICD based functional screen we identified CaNB2 as a modulator of 
AICD-Gal4 mediated transcription. Specifically, we observed that CaNB2 
knockdown in cells that stably carry this reporter system, SH-SY5Y APP Gal4 
cells, leads to a significant decrease in AICD-Gal4 mediated luciferase activity 
when compared to the non-silencing shRNA control (Figure 5-1(A)). To further 
test whether CaNB2 regulates APP metabolism, CaNB2 was overexpressed in 
the same cell line, and a significant increase in AICD-Gal4 mediated luciferase 
activity was observed (Figure 5-1(B)) compared to the empty vector. These 
results suggest that CaNB2 is regulating some aspect of APP metabolism. 
CaNB2 overexpression decreases levels of endogenous FL-APP in HEK293 
cells. 
To test whether CaNB2 alters APP metabolism, CaNB2 was overexpressed in 
HEK293 cells and endogenous levels of FL-APP (APP770 & APP751) were 
measured. Upon CaNB2 overexpression we observed a significant decrease in 
levels of endogenous FL-APP (APP770 & APP751) (Figure 5-2 (A & B)).  
         Next, we wanted to determine if CaNB2 overexpression in HEK293 could 
alter levels of other APP proteolytic products. Therefore, CaNB2 was co-
overexpressed in HEK293 cells along with Swedish APP695. On CaNB2 co-
overexpression we observed no significant change in levels of FL-APP when 
	   161	  
compared to the empty vector control (Figure 5-3(A & B)).  We observed no 
significant changes in APP-CTF levels (C83 and C99) either (Figure 5-4 (A & B)). 
Given that CaNB2 overexpression lead to no change in FL-APP and APP-CTF 
levels, next we used the conditioned media collected from these cells to probe for 
soluble APP levels (s-APP Total). We observed no significant changes in levels 
of sAPP-total with CaNB2 co-overexpression with Swedish APP695 (Figure 5-5(A 
& B)). These results suggest that the effect of CaNB2 might be specific for 
endogenous APP. 
CaNB2 overexpression does not alter APP mRNA levels in HEK293 cells. 
Decrease in levels of endogenous FL-APP observed on CaNB2 overexpression 
could be due its ability to regulate APP mRNA levels. Therefore, we utilized RT-
QPCR to determine if CaNB2 over-expression resulted in decreased APP mRNA 
levels. Overexpression of CaNB2 in HEK293 cells had no significant effect on 
APP mRNA levels suggesting that CaNB2 might  alter endogenous APP levels 
post-transcriptionally (Figure 5-6). 
 
Discussion: 
In our study, we demonstrate that CaNB2 overexpression regulates endogenous 
levels of FL-APP. We had undertaken a systematic search for regulators of APP 
metabolism utilizing an APP-Gal4/Gal4-UAS luciferase reporter system (Zhang et 
al., 2007, Zuchner et al., 2008). Using this approach we identified that CaNB2 as 
a positional candidate gene that could function in regulating APP metabolism. 
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Specifically, we observed that CaNB2 knockdown in SH-SY5Y APP Gal4 cells 
that stably carry this reporter system, leads to a significant increase in AICD-Gal4 
mediated luciferase activity when compared to the non-silencing shRNA control. 
CaNB2 when overexpressed in the same cell line lead to a significant decrease 
in AICD-Gal4 mediated luciferase activity compared to the appropriate empty 
vector. Knockdown and overexpression of the CaNB2 subunit results in 
consistent and opposite effects on APP proteolysis as measured by this assay, 
suggesting that CaNB2 might play a reproducible role in APP metabolism 
regulation in this cellular model. Here, we have extended these initial studies by 
investigating whether CaNB2 expression alters other aspects of APP proteolysis.  
Overexpression of CaNB2 in HEK293 cells lead to a significant decrease 
in levels of endogenous FL-APP. This increase in FL-APP was not observed with 
co-overexpression of APPSwe. No change in proteolytic products like APP-CTF’s 
(C83, C99) & s-APP Total were observed with APPSwe co-overexpression. The 
increase in endogenous APP levels observed are due to post-transcriptional 
effects as no change in APP mRNA levels was observed upon CaNB2 
overexpression. 
        These results can be explained due to specific expression of CaN catalytic 
and regulatory subunits in specific tissues and cell lines.  Three mammalian 
isoforms of CaN A (α, β, γ) have been identified (Shibasaki et al., 2002) and 
CaNAα and CaNAβ are ubiquitously distributed, while CaNA-γ is specifically 
expressed in the testis. CaNB has two mammalian isoforms CaNB1 and CaNB2 
(Rusnak and P. Mertz 2000) and CaNB1 is ubiquitously expressed as a 
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heterodimer with CaNAα or β, while CaNB2 binds to CaNAγ and is expressed 
only in testis. In our studies, we specifically express CaNB2, which needs CaNAγ 
to form a heterodimer and function as an active complex. HEK 293 have been 
shown to express CaNAα and CaNAβ endogenously but presence of CaNAγ has 
not been detected in HEK293 cells. Conversley, SH-SY5Y have been shown to 
express the CaNAγ isoform. Therefore, overexpression of CaNB2 does not 
suggest if CaN complex is being formed and is active. Also, CaNB has been 
shown to have independent gene functions apart from being a part of CaN 
complex. Specifically, CaNB1 has been shown to increase the oncogenic 
potential of HEK293 cells (Wang et al., 2008, Gajewski et al., 2003). Also studies 
have shown that CaNB2 gene is specifically required for indirect flight muscle 
formation in Drosophila (Gajewski et al., 2003). Because, CaNB2 and CaNAγ 
expression is limited to testis (Rusnak and P. Mertz 2000), therefore using a cell 
culture model like HEK293 cells wouldn't be appropriate. However, detection of 
CaNAγ expression in the SH-SY5Y could explain why CaNB2 knockdown 
resulted in altered luciferase activity in SH-SY5Y APP Gal4 cells.  Lastly, CaNB 
has been suggested to have structural role rather than actually regulating the 
function of CaNA and its phosphatase activity, but this topic has been 
controversial.  
Taken together, our results and previous studies indicate that CaNB2 
might have independent gene functions apart from forming a part of the CaN 
complex. Overall, we conclude that increased expression of CaNB2 can 
decrease endogenous levels of APP and can contribute to Alzheimer’s disease 
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by decreasing the levels of Aβ. It is also possible that increased expression of 
CaNB2 might down regulate CaNA activity and lead to decreased expression of 
APP. Therefore, down regulating levels of CaNB2 could be used as a potential 
therapeutic for decreasing Aβ levels after validation in neuronal cell model. 
Experimental Procedures: 
Plasmids: 
CaNB2 (PPP3R2) overexpression plasmid (pCDNA-3) was purchased from 
Open Biosystems. Swedish APP695 plasmid (pCMV-SPORT5) was a generated 
in our lab by mutating APP695	  (pCMV-SPORT5). 
Antibodies: 
Primary antibodies utilized were: a polyclonal antibody raised to the C-terminus 
of APP (A8717; Sigma Aldrich, Inc), an Anti-APP monoclonal antibody was used 
to detect sAPP total levels (22C11, Millipore), a monoclonal anti-β-Actin antibody 
(A5441, Sigma Aldrich, Inc). Secondary antibodies used were: goat anti-Rabbit 
IR-Dye800 CW (926-3211;LiCor Inc.) and/or goat anti-Mouse IR Dye 680 (926-
3200; LiCor Inc.). 
Cell culture and Overexpression experiments: 
HEK-293 cells were purchased from the American Type Culture Collection 
(ATCC) (Manassas, VA). HEK-293 cells were cultured in Dulbecco’s modified 
Eagles medium (DMEM), supplemented with 10% fetal bovine serum, penicillin 
(25,000 U/ml) and streptomycin (25,000 µg/ml). HEK293 cells were then 
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transiently transfected with CaNB2 overexpression construct and an appropriate 
empty vector control.  48 hours post-transfection, cell lysates were collected and 
used for Western Blot analysis. Conditioned media from the above experiments 
was used to detect s-APP levels. 
Western Blot Analysis:  
After the treatments, cells were washed twice with cold PBS and then lysed in 
RIPA Buffer (50 mM Tris, 150 mM NaCl, 1% SDS, 1% NP-40, 0.5% deoxycholate, 
pH 8.0 containing HALT protease and phosphatase inhibitor cocktail 
(ThermoFisher). 10µl of lysates were used for protein assay with the help of BCA 
Protein Assay Kit (Pierce, Inc.). The BCA protein utilizes a standard curve 
generated by RIPA standards (different dilutions of BSA protein in RIPA buffer). 
According to the protein concentrations, samples for Western Blot were prepared 
using the 4x Nupage LDS sample buffer (InVitrogen, Inc.) containing 0.2% BME 
(β-Mercaptoethanol, Sigma Aldrich). Equal volumes of protein were loaded on to 
each well of NuPAGE 4-12% Bis Tris Gel. A molecular weight ladder (Two color 
protein standard, 928-40001, Li-COR) was always run along with the 
experimental samples. From the gel the proteins were transferred on to 0.25 µm 
PVDF membrane (Millipore) using a semi-dry transfer apparatus. Blots were 
probed with different antibodies and the target protein densitometry was 
quantified using the software (ODYSSEY Infra red imaging system, Application 
software) and normalized to the densitometry of β-actin. All Western blot 
experiments were performed in triplicates.  
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RNA extraction and Quantitative PCR: 
48 hours post-transfection, cells were washed with cold PBS and total RNA was 
isolated using RNeasy Mini Kit (Qiagen Inc.). To quantify APP mRNA levels, 
cDNA was synthesized using total RNA, N6 random primers and SuperScript II 
Reverse Transcriptase (Invitrogen). cDNA was then diluted 1:15 using RNase 
free water and mixed with APP or GAPDH primer/probe sets (Applied 
Biosystems, Inc.; APP Catalog # Hs00169098_m1; GAPDH Cat- alog # 
Hs99999905_m1), 2× PCR Universal Master Mix (Applied Biosystems, Inc.) and 
amplified using an ABI 7500 Real Time PCR system following the manufacturer's 
directions. GAPDH was used as an internal control. To determine differences in 
APP mRNA levels, we utilized the ΔΔCt method. 
Statistical Analysis: 
Values in the text and figures are presented as means ± standard errors of at 
least three independent experiments. Equal variance or separate variance two-
sample student’s t-test were used, as appropriate, to compare two groups. “*” 
indicates p < 0.05, “**” indicates p < 0.01, and “***” indicates p < 0.001. “n.s.” 
indicates p-values greater than 0.05. 
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FIGURES: 
 
 
 
    
Figure 5-1A. CaNB2 knockdown increases AICD-mediated luciferase 
activity. SH-SY5Y APP-Gal4 cells expressing APP-Gal4 and Gal4-UAS 
Luciferase were used to monitor AICD-Gal4 mediated luciferase activity. 
Luciferase activity was measure in response to Knockdown of CaNB2, APP, Luc 
or control. Values are means ± standard errors of 3 independent experiments. 
“*”: p < 0.05 (Student’s t-test). 
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Figure5-1B. CaNB2 decreases AICD-mediated luciferase activity. SH-SY5Y 
APP-Gal4 cells expressing APP-Gal4 and Gal4-UAS Luciferase were used to 
monitor AICD-Gal4 mediated luciferase activity. Luciferase activity was measure 
in response to CaNB2 overexpression. Values are means ± standard errors of 3 
independent experiments. “***”: p < 0.001 (Student’s t-test). 
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Figure 5-2. CaNB2 overexpression in HEK293 cells alters levels of 
endogenous APP. CaNAβ was overexpressed in HEK293 cells. An empty 
vector was overexpressed as the control for the experiment. (A) Representative 
western blot from the above experiment showing a decrease in levels of 
endogenous FL-APP when CaNB2 is overexpressed. (B) Quantification shows a 
significant decrease in levels of endogenous FL-APP. β-Actin was used as a 
loading control. 
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Figure 5-3.  CaNB2 co-overexpression with APP Swe in HEK293 cells to 
detect FL-APP levels. CaNB2 and APP Swe were co-overexpressed in HEK293 
cells. (A) Western blot analysis on cell lysates from HEK293 overexpressing 
CaNB2 and APP swe.  (B) No Significant change in levels of APP-CTF was 
observed. β-Actin was used as the loading control. Values are means ± standard 
errors of 3 independent experiments. . “*”: p < 0.05, “***” :p < 0.001 and “n.s.” : p-
values > 0.05 (Student’s t-test). 
 
 
	  	  Control 	  	  	  CaNB2 
β-­‐Actin 
	   APPm APPim 
0	  20	  
40	  60	  
80	  100	  
120	  140	  
160	  
PF-­‐3+APP	  Swe	   PPP3R2+APP	  Swe	  
N
or
m
al
iz
ed
	  D
en
si
to
m
et
ry
	  
	  Control+	  APP	  Swe CaNB2	  +	  APP	  Swe 
A	  
B	  
	   171	  
 
 
 
Figure 5-4. CaNB2 co-overexpression with APP Swe in HEK293 cells to 
detect APP-CTF levels. CaNB2 and APP Swe were co-overexpressed in 
HEK293 cells. (A) Western blot analysis on cell lysates from HEK293 
overexpressing CaNB2 and APP swe.  (B) No Significant change in levels of 
APP-CTF was observed. β-Actin was used as the loading control. Values are 
means ± standard errors of 3 independent experiments. . “*”: p < 0.05, “***” :p < 
0.001 and “n.s.” : p-values > 0.05 (Student’s t-test). 
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Figure 5-5. CaNB2 co-overexpression with APP Swe in HEK293 cells to 
measure s-APP levels. CaNB2 and APP Swe were co-overexpressed in 
HEK293 cells. (A) Western blot analysis on conditioned media from HEK293 
overexpressing CaNB2 and APP swe.  (B) No Significant change in levels of s-
APP Total was observed. Values are means ± standard errors of 3 independent 
experiments. . “*”: p < 0.05, “***” :p < 0.001 and “n.s.” : p-values > 0.05 (Student’s 
t-test). 
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Figure 5-6. CaNB2 overexpression does not alter APP mRNA levels in 
HEK293 cells. Q-PCR results from this experiment showed that CaNB2 does not 
regulate APP transcription. “*”: p < 0.05, “***” :p < 0.001 and “n.s.” : p-values > 
0.05 (Student’s t-test). 
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CHAPTER 6: DISCUSSION 
Alzheimer's disease (AD) is a progressive neurodegenerative brain disorder that 
slowly destroys memory and cognitive skills (Strassnig and M. Ganguli 2005). 
Senile plaques (SPs) and neurofibrillary tangles (NFTs) are the two key 
pathological hallmarks of AD (Strassnig and M. Ganguli 2005). NFTs are made of 
the hyperphosphorylated form of a protein called Tau and are found within 
neurons whereas senile plaques are made up of amyloid-beta (Aβ) peptide and 
are found in the extracellular space (De Strooper and W. Annaert 2000).  Aβ 
formation occurs on sequential cleavage of the β-amyloid precursor protein 
(APP) by the β and γ secretase, followed by release of Aβ into the extracellular 
space (De Strooper and W. Annaert 2000). Therefore, APP metabolism and 
Aβ production are considered central events in AD. High levels of Aβ have been 
related to hyperactivation of calcineurin (CaN) (Kuchibhotla et al., 2008, Wu et al., 
2010, Loo et al., 1993). CaN also plays a very important role in AD.  CaN, being 
a serine/threonine specific phosphatase, has been associated with 
dephosphorylation of many genes that are an important part of the signaling 
pathways contributing to AD. Specifically, CaN has been shown to mediate the 
neurodegenerative effects of Aβ (Reese et al., 2008, Wu et al., 2010, Agostinho 
et al., 2008, Abdul et al., 2009, Loo et al., 1993). Aβ produced by the 
amyloidogenic processing of APP is responsible for perturbing the intracellular 
levels of Ca2+ (Reese et al., 2008). Specific species of Aβ can aggregate to form 
Ca2+ channels in synthetic bilayer membranes (Arispe et al., 1993). Oligomeric 
species of Aβ alter the cytosolic Ca2+ levels by cellular membrane disruption 
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(Reese et al., 2008). Ca2+ dyshomeostasis leads to activiation of various kinases 
and phosphatases including the serine/threonine phosphatase CaN. CaN 
hyperactivation results in dephosphorylation of numerous genes thought to play a 
role in AD pathogenesis, including phospho-CREB (Bito et al., 1996), phospho-
NFAT (Abdul et al., 2009), phospho-Tau (Liu et al., 2005), phospho-BAD (Wang 
et al., 1999, Asai et al., 1999, Dineley et al., 2007) and phospho-Gsk3β  (Kim et 
al., 2009). Discussed below are the details of how CaN dephosphorylates these 
individual genes and contributes to AD pathogenesis by instigating loss of 
synaptic plasticity, dendritic spine loss, microtubule dysfunction, apoptosis, and 
excitotic cell death. 
      Dephosphorylation of the transcription factor CREB (cyclic-AMP response 
element binding protein) by CaN leads to its inactivation and inhibition of CREB 
mediated gene expression (Bito et al., 1996). Once phosphorylated by Ca2+ 
dependent and independent protein kinases, CREB translocates into the nucleus 
where it activates gene transcription (Bito et al., 1996). CREB is involved in 
transcription of several genes including those encoding brain derive neurotrophic 
factor (BDNF) and nitric oxide synthase, BDNF and its receptor tropomyosin 
related kinase B (trkB). Transcription of these genes play a role in processes like 
LTP, synaptic plasticity, neuronal growth and survival (Lonze and D. D. Ginty 
2002, Shaywitz and M. E. Greenberg 1999, Benito and A. Barco 2010, Tao et al., 
1998, Huang and L. F. Reichardt 2003). Aβ mediated activation of CaN is hence 
responsible for inhibition of CREB mediated gene transcription leading to loss of 
synaptic plasticity (Bito et al., 1996, Shibasaki et al., 2002, (Agostinho et al., 
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2008, Reese et al., 2008, Mukherjee et al., 2010, Dineley et al., 2010). Since 
synaptic changes are a central pathological event in AD, 
Aβ induced dysruption of CaN signaling through CREB plays a critical role in AD 
pathogenesis. 
      NFAT (nuclear factor of activated T-cells) again is a very significant and well-
characterized transcription factor that contributes to AD pathogenesis (Graef et 
al., 2003, Groth and P. G. Mermelstein 2003). In its phosphorylated state, NFAT 
localizes to the cytoplasm. Dephosphorylation of NFAT leads to exposure of its 
nuclear localization signal, followed by its translocation into the nucleus. Once in 
the nucleus, it is involved in transcription of many important genes involved in 
neuronal survival, axonal outgrowth, dendritic complexity, cytokine production 
and inflammation (Graef et al., 2003, Groth and P. G. Mermelstein 2003, 
Schwartz et al., 2009). Aberrant CaN hyperactivity induced by Ca2+ 
dyshomeostasis due to increased Aβ levels leads to NFAT translocation into the 
nucleus and increased NFAT mediated transcription. This further leads to 
induction of morphological neurodegenerative abnormalities like loss of dendritic 
spines, dendrite simplification, neuritic dystrophic and dendritic spine loss (Wu et 
al., 2010). Activation of a specific NFAT, NFAT1 gene, has been observed in 
brains of Tg2576 mouse (AD mouse model overproducing Aβ also observed with 
CaN hyperactivity) along with increased BACE1 expression(Cho et al., 2008). It 
has been suggested that NFAT activation mediated by CaN can lead to 
increased production of β-secretase (BACE-1) (Cho et al., 2008).  β-secretase is 
the enzyme involved in amyloidogenic processing of APP and may eventually 
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contribute to altered levels of Aβ (De Strooper and W. Annaert 2000). Therefore, 
Aβ can activate the CaN/NFAT pathway, which can further alter Aβ levels and 
contribute to AD. 
         Dephosphorylation of Tau by CaN also plays a fundamental role in AD. 
CaN isolated from the human brain dephosphorylates, Tau at Ser-262 and Ser-
396 indicating its role in neurofibrillary tangles associated degeneration in AD 
(Rahman et al., 2006). Tau is a microtubule associated binding protein (MAP) 
(Goedert et al., 1991), which facilitates the assembly and organization of 
microtubules involved in the transport between neurons (Goedert et al., 1991). 
Tau, in its phosphorylated state, has less affinity for microtubules, which leads to 
its disassociation leading to depolymerization of microtubules (Lindwall and R. D. 
Cole 1984, Drechsel et al., 1992). Hyperphosphorylation of Tau leads to 
formation of paired helical filaments referred to as neurofibrillary tangles (NFT) 
(Sontag et al., 1996, Liu et al., 2005). NFTs are a pathological hallmark of AD is 
directly correlated to the severity in dementia symptoms (Arriagada et al., 1992, 
Riley et al., 2002). CaN is one of the major phosphatases involved in 
dephosphorylation of Tau (Drewes et al., 1993, Goto et al., 1985, Gong et al., 
1994). It has been suggested by several research groups that decreased CaN 
activity reported in the AD brains might be responsible for hyperphosphorylation 
of Tau in AD brains (Gong et al., 1994). Increased levels of endogenous inhibitor 
of CaN named Calcipressin also supports the above hypothesis (Ermak et al., 
2001). But, recently there have been reports suggesting that increased CaM 
levels in the brains of AD patients lead to impaired binding between Tau and 
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CaN (Yu et al., 2008). Also, SH-SY5Y cells treated with CaN inhibitors, 
exhibiting a decrease in CaN activity also show an increase in extracellular 
ptau 181. The same study also observed this in AD patients, who have 
elevated CSF ptau 181 and reduced CaN activity in brain extracts(Karch et al., 
2013). Hence, altered activity of CaN is might play an essential role in 
microtubule integrity through regulating the phosphorylation of Tau and 
contribute significantly to AD pathogenesis. 
           CaN plays an important role in neurodegeneration by regulating the 
phosphorylation of pro-apoptotic protein called BAD (Bcl-2 associated death 
protein) (Shou et al., 2004, Wang et al., 1999). Normally phosphporylated BAD is 
usually found to be associated with scaffolding proteins. CaN induced 
dephosphorylation leads to disassociation of BAD from its scaffolding protein and 
localization into the mitochondria. Once translocated into the mitochondria, BAD 
interacts with the members of Bcl-2 family of proteins forming proapoptotic 
dimers and lead to release of cytochrome c eventually leading to apoptosis 
(Agostinho et al., 2008, Reese et al., 2008). Therefore, CaN hyperactivity can 
lead to apoptosis observed in AD brains. 
          There have also been reports showing that the kinase Gsk3β plays a very 
important role in regulating the phosphorylation of Tau and APP (Hanger et al., 
1992, Kim et al., 2009).  CaN has been shown to dephosphorylate Gs3kβ leading 
to its activation (Kim et al., 2009). Gsk3β once activated, phosphorylates Tau at 
the same residues found to be phosphorylated in the AD brains. Its also 
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phosphorylates APP at Thr668 residue. Phosphorylation of Thr668 residue of 
APP is involved in regulating its cleavage by different secretases (Feyt et al., 
2007). This modulated cleavage of APP by different secretase might result in 
altered Aβ levels. Therefore CaN hyperactivity can control the Gsk3β mediated 
phosphorylation of APP and Tau and control the formation of the two major 
patho-biological hallmarks of AD (NFT & Aβ plaques). 
         CaN’s role in promoting LTD over LTP has also been well studied. LTP and 
LTD depend on the amount of Ca2+ influx through NMDA (N-methyl D-aspartate) 
receptors and activation of metabotropic glutamate receptors (mGluRs) (Kemp 
and Z. I. Bashir 2001, Wu et al., 2006, Harney et al., 2006, Anwyl 2006, Citri and 
R. C. Malenka 2008). High levels of Ca2+ flowing in through NMDA receptors 
leads to LTP, whereas low levels of Ca2+ influx through NMDA receptors leads to 
LTD (Kullmann and K. P. Lamsa 2007). CaN is known to be an important 
phosphatases involved in LTD (Kemp and Z. I. Bashir 2001, Citri and R. C. 
Malenka 2008). Increased Aβ levels are involved in internalization of NMDA 
receptors via a mechanism involving CaN and leads to decrease in the influx of 
Ca2+. As discussed above, increased levels of oligomeric Aβ are also involved in 
CaN mediated dephosphoryltion of CREB and its inactivation. CaN mediated 
dephosphorylation of CREB inhibits the transcription of several genes including 
BDNF (brain derived neurotrophic factor) and nitric oxide synthase (Mayr and M. 
Montminy 2001, Mayr et al., 2001). These series of events promote LTD over 
LTP and link Aβ-CaN to the cognitive dysfunction observed in AD. 
       Lastly, Aβ and CaN’s role in synaptic dysfunction plays an essential role in 
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AD. Presence of CaN in presynaptic and postsynaptic terminals accounts for its 
role in synaptic transmission. CaN regulates the processes like endocytosis and 
exocytosis controlling the release of neurotransmitters at pre-synaptic terminals. 
It has been shown that CaN dephosphorylates syanpsin I which is involved in 
tethering of neurotransmitter containing vesicles to the cytoskeleton (Jovanovic 
et al., 2001). Dephosphorylation hinders the ability of synapsin I-associated 
vesicles to move from the vesicle pool, inhibiting the release of neurotransmitters 
(Sun et al., 2010). At the post-synaptic terminals, CaN is involved in 
dephosphorylation of NMDA receptors leading to its desensitization and less 
mean open time. Similarly it is known to increase the desensitization period of 
other receptors like GABA, acetylcholine and serotonin receptors. Therefore, 
once again Aβ mediated CaN activation can contribute in AD by playing an 
essential role in synaptic plasticity. 
        Therefore we conclude that increased Aβ levels   and specifically formation 
of oligomeric Aβ  leads to its own aggregation and accumulation. This 
Aβ accumulation  further triggers an inflammatory response leading to microglial 
activation and cytokine release, further causing progressive neuritic injury leading 
to disruption of metabolic and ionic homeostasis in neurons. This chain of events 
further lead to altered kinases and phosphatases activity including CaN. To 
summarize the above, CaN mediated dephosphorylation of specific target genes 
(mentioned above) may account for its role in synaptic protein loss, 
neuroinflammation (neuronal and astrocytic), decreased neurotransmission, 
hyperphosphorylated tau, and cell death. Hence, it is very apparent that Aβ and 
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CaN work together to facilitate AD pathogenesis. But, what is not clearly known 
is if CaN can regulate levels of Aβ and the mechanism underlying it. 
         As discussed above, CaN has been previously associated with 
neurodegenerative effects of Aβ. In addition, it has been also shown that FK506 
mediated inhibition of CaN phosphatase activity ameliorates the Aβ mediated 
neurodegenerative affects. What is not clearly known is the mechanism by which 
CaN regulates Aβ levels.  It is possible that CaN and Aβ form a feed-back loop 
governing the Aβ production and CaN activation (Figure 6-1). In our study we 
specifically (i) study the role of CaN in APP metabolism and investigate the 
mechanism by which FK506 mediated inhibition of CaN leads to a decrease in 
Aβ levels  in vitro and in vivo ,(ii) demonstrate that FK506 treatment recapitulates 
the improvements previously observed in rodent transgenic AD models in our 
transgenic Drosophila AD model (iii) Correlate the clinically observed high levels 
of CaNAβ mRNA’s in brains of AD patients to the experimentally observed 
increase in Aβ levels in vitro, on CaNAβ overexpression. 
     CaNAβ has been previously identified as one of the most up-regulated genes 
in brain lesions of the early stage of AD. The same study also confirmed that 
CaNAβ was generally upregulated in the hippocampus of the early stage of AD 
using RT-PCR analysis (Hata et al., 2001, Chakraborty et al., 2011). The exact 
mechanism for upregulation of CaNAβ in the AD brain is not clear. Using an 
AICD based functional screen established in SH-SY5Y APP Gal4 cells, we also 
identified CaNAβ as a potential regulator of APP metabolism. We observed the 
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CaNAβ overexpression and knockdown could reversibility regulate levels of AICD. 
Also pharmacological inhibition of CaN using FK506 lead to a decrease in levels 
of AICD both in SH-SY5Y APP Gal4 cells and in γ- secretase reporter flies 
(Utreja et al, Chap 2). 
       Therefore, we next wanted to determine if FK506 mediated inhibition of CaN 
can alter levels of other APP proteolytic products. Using Drosophila AD model 
and rat cortical neurons as our invivo and invitro models we investigated the 
affects of FK506 mediated inhibition of CaN on APP metabolism. We observed 
an increase in APP-CTF’s and a decrease in levels of Aβ in both the models. No 
change in levels of FL-APP, sAPP-total and sAPP-β were observed invitro.             
             An increase in levels of APP-CTF’s and a decrease in levels of Aβ with 
no significant changes in levels of FL-APP can be explained by inhibited γ-
secretase cleavage of APP-CTF’s. We also observed an increase in levels of 
Thr668 phosphorylation of APP-CTF’s on FK506 treatment. Based on the several 
theories that suggest that Thr668 phosphorylation of APP-CTF’s can/cannot alter 
Aβ production, we tested if FK506 treatment of Thr668-Ala mutant of APP also 
shows affects similar to Wt-APP. We observed that Thr668-Ala mutant of APP 
showed a similar increase in APP-CTF’s levels but the increase was to a lesser 
extent. These experiments suggested that CaN can inhibit γ-secretase cleavage 
of APP-CTF’s and hence lead to low Aβ levels. This inhibition of cleavage might 
be dependent on the ability of CaN to alter the phosphorylation state of APP at 
Thr668. Further investigation is necessary to confirm these results in rat cortical 
neurons as the experiments performed in HEK293 cells with Thr668 Ala mutant 
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of also lead to an increase in FL-APP levels apart from increased APP-CTF 
levels with FK506 treatment. This increase in FL-APP was similar to our fly data 
where APP is exogenously being overexpressed. Also, the inhibited γ-sectrease 
cleavage/activity is specific to APP as no change in the levels of NICD was 
observed. FK506 treatment of cells transfected with ΔE-Notch (well known 
substrate of γ-sectrease) did not show any change in levels of NICD (a proteolytic 
product of Notch) suggesting that this inhibition of cleavage by γ-secretase is 
specific to APP. Overall, we conclude that pharmacological inhibition of CaN 
regulates APP metabolism leading to a decrease in Aβ levels. This regulation 
could be dependent on change in phosphorylation state of APP at Thr668, ability 
of CaN to affect the sub-cellular localization of APP and regulate its accessibility 
to γ-sectrease or CaN mediated dephosphorylation of APP at other residues 
apart from Thr668 (Utreja et al, Chap 2).  
         We recapitulated our results in vivo utilizing the double transgenic 
Drosophila model of AD, which stably overexpresses human APP and human 
BACE in the central nervous system and recapitulates amyloidogenic processing 
of APP leading to production of Aβ  (Chakraborty et al., 2011). This model has 
been previously shown to have several morphological, neuroanatomical and 
cognitive deficits. L-685,458 treatment of these AD flies have shown to improve 
these deficits by inhibiting the γ-secretase activity in these flies leading to 
decreased production of Aβ (Chakraborty et al., 2011). Pharmacological inhibition 
of CaN using FK506 in these flies lead to a similar decrease in levels of Aβ and 
rescued Aβ mediated cognitive, neuroanatomical and neurodegenerative defects 
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(Utreja et al, Chap 2).  Our study also showed that CaN inhibition alters APP 
processing in vivo, and this altered APP cleavage might be due to inhibition of γ-
secretase mediated cleavage of APP-CTF’s.  Overall the data suggests that 
these deficits observed in AD model are dependent on levels of Aβ and FK506 
mediated inhibition of CaN leads to decrease in levels of Aβ, ameorialiting these 
defects. 
        Lastly, in our study we also investigated how increased levels of 
CaNAβ observed in early stages of AD brain  could be associated with 
neurodegenerative affects of Aβ. CaNAβ as discussed previously has been 
identified as one of the most upregulated genes of brains of AD. Therefore, we 
overexpressed CaNAβ  in HEK293 cells to determine if it could alter APP 
processing and Aβ  levels. On its overexpression we observed an increase in 
levels of FL-APP, APP-CTF’s, s-APP total and Aβ40 levels. Therefore, we could 
correlate the increase in levels of Aβ to clinically observed increase in levels of 
CaNAβ (Utreja et al, Chap 3).  These results provide a concrete base for further 
investigating how CaNAβ regulates APP metabolism.   
         This study is the first to relate the levels and activity of CaN to APP 
metabolism. Our data shows pharmacological inhibition of CaN decrease levels 
of Aβ by regulating APP metabolism. This regulation seems to dependent on 
inhibited γ-secretase dependent cleavage of APP-CTF’s. Phosphorylation 
changes of APP at residue Thr688 can possibly be responsible for inhibiting the 
cleavage of APP by γ-secretase. As discussed previously the role of Thr668 in 
modulating the cleavage of APP by different secretases and affecting levels of 
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Aβ is controversial. In future, it will be important to dissect the ability to of CaN to 
alter Thr668 phosphorylation of APP and confirm its role in regulation of APP 
metabolism via CaN. Investigating the role of CaN in modifying the 
phosphorylation of other residues on APP-CTF’s such as Tyr653, Ser655, 
Thr668, Ser675, Tyr682, Thr686 and Tyr687 which could also play a role in 
regulating the cleavage of APP by γ-secretase would help us determine if CaN 
can alter the phosphorylation of more than one particular residues on APP 
(Figure 6-2).  CaN has been associated with regulation of endocytosis by its 
ability to dephosphorylate Dynamin 1 (a GTPase). Dynamin 1, once 
dephosphorylated plays a significant role in endocytosis. Inhibition of CaN can 
possibily lead to downregulation of endocytosis of APP or γ-secreatse present at 
the plasma membrane. Therefore, it will be important to monitor the subcellular 
localization of APP & γ-secretase components when CaN is pharmacologically 
inhibited, to determine if APP’s accessibility to γ-secretase (vice versa) has been 
restricted leading to inhibition of its cleavage. Determining if overall γ-secretase 
activity is being inhibited on inhibition of CaN using γ-secretase activity assay wlll 
also be necessary. Hence testing for ability of CaN to dephosphorylate APP or 
alter APP/γ-secretase localization will be two important questions that should be 
investigated in future (Figure 6-3). 
      Overall, exploring the individual role and the mechanism by which CaN 
(activity and its protein levels) contribute in AD pathogenesis, will help in better 
understanding of its use a potential AD therapeutic target.   
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Figure 6-1. CaN, Aβ, APP: Increase in Aβ levels is associated with AD. High 
levels of Aβ leads to calcium dyshomeostasis. Increased levels of calcium 
activate phosphatase CaN and downstream signaling pathways. Inhibition of 
CaN activity using FK506 is associated with improvement of Aβ mediated 
neurodegenerative effects. In our study we show that inhibition of CaN regulates 
APP metabolism and leads to a decrease in Aβ levels. 
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Figure 6-2. APP Phosphorylation residues: Altered Thr668 phosphorylation of 
APP can possibily regulate APP cleavage by γ-secretase and lead to decreased 
levels of Aβ. Investigating the role of Thr668 phosphorylation along with the other 
six phosphorylation residues on APP would be important to identify the exact 
mechanism responsible of altered APP cleavage. 
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Figure 6-3. Future Directions: Determining if Thr668 PO4- &/or phosphorylation 
of other residues on APP are being altered upon CaN inhibition or γ-secretase 
acitivity or accesbility is being affected upon CaN inhibition. 
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